EMBLA MEDICAL®

FINANCIAL STATEMENTS

2025

FINANCIAL STATEMENTS

Consolidated Financial Statements

TABLE OF CONTENTS

Statement by the Board of Director and President and CEO

Embla Medical is a global leader in non-invasive orthopedics, innovating, producing, and providing advanced technological solutions within the prosthetics, neuro orthotics and bracing & supports market. The Company also provides patient care through a global network of Orthotic and Prosthetic (O&P) facilities. Embla Medical's mission is to improve the mobility of our end-users so they can live their Life Without Limitations®. The Company is headquartered in Iceland and owns and operates subsidiaries in multiple countries around the world. The Company sells its products worldwide, but its principal markets are Europe and North America. The Consolidated Financial Statements of Embla Medical hf. as at and for the year ended 31 December 2025 comprise Embla Medical hf. and its subsidiaries (together referred to as "the Company" or "Embla Medical").

Embla Medical's Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards (IFRS) accounting standards as adopted by the European Union and additional requirements in the Icelandic Annual Accounts Act no. 3/2006.

Operations in 2025

The total net sales of the Company amounted to USD 928.7 million (2024: USD 854.9 million). Organic sales increase was 6%. Net profit amounted to USD 83.6 million (2024: USD 69.0 million). Basic and diluted earnings per share amounted to US cents 19.6 (2024: US cents 16.2). Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to USD 185.9 million and 20% of sales (2024: USD 169.1 million, 20%).

The total assets of the Company amounted to USD 1,730.5 million at year end (2024: USD 1,539.0 million), total liabilities were USD 834.7 million (2024: USD 758.3 million) and total equity was USD 895.8 million (2024: USD 780.7 million). The equity ratio at year end was 52% (2024: 51%).

The Company employed an average of 4,138 employees in 2025 (2024: 4,091) and 4,192 at year end (2024: 4,078). Information regarding salaries and salary related expenses can be found in note 6.

In 2025 Embla Medical managed to grow the business across all regions and business segments. Sales grew 6% organically and 7% including acquisitions. Growth in 2025 was driven by Prosthetics & Neuro Orthotics and Patients Care mainly with a strong performance in EMEA and supported by recently launched innovation. Gross profit margin was 62%, compared to 63% in 2024. The gross profit margin was positively impacted by strong sales in P&NO and efficiency gains in manufacturing but was offset by negative impact from FX, tariffs and turnaround initiatives in Patient Care

No subsequent events occurred after the balance sheet date that would require disclosure in the Consolidated Financial Statements.

Shareholders and share price

Embla Medical's shares are admitted to trading on the Nasdaq Copenhagen stock exchange. The market value of the Company at year end was USD 2,202 million (2024: USD 2,125 million). The share price in DKK amounted to 32.5 at year end (2024: 35.6) and decreased by 8.7% during the year. At year end, registered shareholders in Embla Medical were 6,718 compared to 6,095 at the beginning of the year. It should be noted that due to the concentration of trading in Nasdaq Copenhagen in 2017, about 1,600 shareholders that held shares listed in Iceland were consolidated into a few nominee accounts. The ten largest shareholders and their ownership percentage (net of treasury shares) are: William Demant Invest A/S – 50.95%, Interogo Holding AG – 11.54%, Live Pension Fund – 6.05%, Arbejdsmarkedets Tillægspension – 5.03%, SEB Investment Management – 4.05%, Gildi Pension Fund – 3.48%, LSR Pension Fund – 2.68%, Handelsbanken Fonder – 1.49%, Birta Pension Fund – 1.19%, ODIN Fonder – 1.16%. William Demant Invest A/S (WDI) ownership in Embla Medical exceeded 50% in January 2018. According to WDI's announcement at the time, their intention is to hold 50-60% of Embla Medical's shares going forward and they have no intention of taking over Embla Medical or delisting Embla Medical's shares from Nasdaq Copenhagen. Furthermore, WDI has no intention of making changes to Embla Medical's strategy, management or operations.

Statement by the Board of Director and President and CEO

Embla Medical shares and share contracts

Embla Medical's total share capital is 430.4 million shares with a nominal value ISK 1 each. In 2025 in connection with the acquisition of Streifeneder ortho.production, new shares were issued raising the total share capital in nominal value by 0.7%, from ISK 427.6 million to ISK 430.4 million resulting in USD 15 million increase in share capital. At year end 2025 Embla Medical held 2.7 million treasury shares that equals to 0.6% of issued shares. The remaining treasury shares held will be used to fulfill obligations under share option agreements that have vested or will be vesting in 2026. Share contracts are granted to management and key leaders. In 2024 a new long term incentives program of performance share units ("PSUs") and restricted shares units ("RSUs") was initiated in accordance with approval at the Company's Annual General Meeting for 2023. This program replaced the previous share options plan. Total granted and unexercised share options and share units at year end 2025 were 2.4 million shares (2024: 3.9 million shares), of which 1.2 million are exercisable before year end 2026 and the remaining in 2027-2028. See further information in note 24.

Dividend proposal

In line with the Company's Capital Structure and Capital Allocation Policy, the Board of Directors will propose to the Annual General Meeting in 2026 not to pay a cash dividend. With emphasis on prioritizing investments in growth opportunities, value-adding investment opportunities and acquisitions, Embla Medical has decided to discontinue dividend payments and focus on returning excess capital to shareholders via purchase of treasury shares in accordance with the Company's Capital Structure and Capital Allocation Policy.

Corporate governance and risk management

The Company follows the Danish Recommendations for Corporate Governance issued by the Danish Committee on Corporate Governance, available at: https://corporategovernance.dk/. The Board of Directors complies with applicable Icelandic laws and regulations, the Articles of Association of the Company and the Board of Directors' Rules of Procedure, which addresses the Board's role and responsibilities. The Company's management structure consists of the Board of Directors and the Executive Management, led by the President and CEO. The two bodies are separate, and no person serves as a member of both. The Board of Directors is composed of six members elected by shareholders at each Annual General Meeting for a term of one year. The Board of Directors consists of three women and three men and is in compliance with Icelandic law on gender ratio. No Embla Medical employee sits on the Board of Directors. The President and CEO manages the Company's daily operations.

The Board of Directors has established three committees, the Audit Committee, the Nomination Committee and the Remuneration Committee. The Audit Committee has three members from the Board, who are appointed by the Board of Directors for a term of one year. The Chairman of the Board and the Chairman of the Audit Committee serve on the Nomination Committee together with the President & CEO and the Remuneration Committee. The committees comply with their respective Terms of Reference, which address their role and responsibilities etc.

An investment in Embla Medical involves various risks as the business, financial conditions, and operational results rest upon certain assumptions and could have negative affect the Company. Even though the long-term prospects and underlying fundamental drivers of our markets are not expected to change, Embla Medical highlights key risks which are currently considered the most relevant. The key risks identified are: reimbursement landscape, regulatory requirements, new technologies, industry consolidation, forward integration and acquisitions. Further description of these risks as well as other relevant material risks that Embla Medical faces can be found in the Risk Management chapter of the Annual Report and Company's website. Information about financial instruments and financial risk management can be found in note 34.

The Board of Directors has an ongoing dialogue with the President and CEO on the identification, description and handling of the business risks to which the Company may be exposed. The Company's control framework in relation to financial processes, is designed to mitigate risk of material misstatements. The Company designs its processes to ensure there are no material weaknesses with internal controls that could lead to a material misstatement in its financial reporting. The external auditor's role in these processes is included in the independent auditor's report.

Statement by the Board of Director and President and CEO

Sustainability at Embla Medical
Sustainability is embedded into Embla Medical's strategy and throughout its organization. The Company has a robust sustainability agenda and captures its commitment under the theme of Responsible for Tomorrow® recognizing that the decisions and actions taken today, will affect future generations.

The Company's Sustainability Commitment is to provide products and services that contribute to good health, using responsible production methods and supporting climate action, while being a sponsor for inclusivity and transparency. It is believed that sustainable growth is the only way to build a successful and responsible business for the benefit of future generations.

Our Environment
Embla Medical takes responsibility for its environmental impact, has set science-based targets and is actively working towards Net-zero operations by 2050. It is reducing the environmental impact in the supply chain, and of the products and services.

Our People
The Company takes responsibility for enhancing the social well-being of the people across its value chain. It develops quality products and services that improve people's mobility, nurtures the well-being and development of its employees within a safe and inclusive work environment. Embla Medical partners with suppliers that are committed to quality, and ethical and sustainable practices, and creates a lasting positive impact on the communities, helping more people to live a Life Without Limitations®. Multiple policies have been approved and implemented to support and guide the employees and other stakeholders. Embla Medical's policies are available on the Company's website: https://emblamedical.com/policies.

Our Business
The Company leads its business with integrity and transparency, promoting sound governance practices in all its activities. In accordance with its values, Embla Medical sets high ethical standards, and has a zero-tolerance policy when it comes to corruption and bribery. The Company guides its employees through the Code of Conduct and offers platforms for them and other stakeholders to voice any potential concerns through the Embla Medical Speak-Up line. The Board approves a Corporate Governance report that includes all the information to be included in the statutory statement referred to in Article 66 (c) of the Icelandic Act Annual Accounts no. 3/2006, as well as explanations, comments and information on each recommendation in the Danish Recommendation for Corporate Governance. The report is available on the Company's website: https://www.emblamedical.com/investor-relations/reports-and-presentations.

The Icelandic Annual Accounts Act no. 3/2006 requires companies in Iceland to conclude on non-financial information in the Annual Report. For 2025, we are disclosing the information regarding sustainability in reference to the Corporate Sustainability Reporting Directive and European Sustainability Reporting Standards, and including reporting on sustainable finance in line with the EU Taxonomy Regulation. Embla Medical has obtained limited assurance according to ISAE 3000 on selected sustainability data included in the Sustainability Statement chapter in the Annual Report. Embla Medical is required by the EU Taxonomy to disclose its alignment and eligibility of turnover, operating expenses and capital additions with six environmental objectives stated in the EU 2020/852 regulation. The results can be found in Sustainability statement chapter in the Annual Report.

Statement by the Board of Directors and the President and CEO
According to our best knowledge, it is our opinion that the Consolidated Financial Statements give a true and fair view of the consolidated financial performance of the Company for the year 2025, its assets, liabilities and consolidated financial position as at 31 December 2025 and its consolidated cash flows for the year 2025. Furthermore, it is our opinion that the financial statements and the report of the Board of Directors and the President and CEO contain a clear overview of developments and results in the Company's operations, its position and describe the main risk factors and uncertainties facing the Company.

In our opinion, the Sustainability Statement included in the Annual Report represents a reasonable, fair, and balanced representation of the Company's sustainability performance and are prepared in accordance with the stated accounting policies. Furthermore, disclosures within subsection "EU Taxonomy KPIs" in the environmental section of the Sustainability Statement are, in all material respects, in accordance with Article 8 of EU Regulation 2020/852 (the "Taxonomy Regulation").

Statement by the Board of Director and President and CEO

In our opinion, the Consolidated Financial Statements of Embla Medical hf. for the financial year 2025 identified as "EmblaMedical-2025-12-31.zip" are prepared in all material respects, in compliance with the ESEF Regulation.

The Board of Directors and President and CEO of Embla Medical hf. hereby confirm the Consolidated Financial Statements of Embla Medical for the year 2025 with their signatures.

Reykjavík, 3 February 2026

Board of Directors

Niels Jacobsen
Chairman of the Board

Svafa Grönfeldt
Vice Chairman of the Board of Directors

Arne Boye Nielsen
Member of the Board of Directors

Alberto Esquenazi
Member of the Board of Directors

Tina Abild Olesen
Member of the Board of Directors

Caroline Vagner Rosenstand
Member of the Board of Directors

President and CEO

Sveinn Sölvason

Independent Auditor´s Report

To the Board of Directors and the Shareholders of Embla Medical hf.

Opinion

We have audited the accompanying Consolidated Financial Statements of Embla Medical hf. and its subsidiaries (the Company) for the year 2025, excluding the Statement by the Board of Directors and President and CEO.

In our opinion, the Consolidated Financial Statements give a true and fair view of the consolidated financial position of the Company as at December 31, 2025, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with IFRS accounting standards as adopted by the European Union (EU), and applicable articles in Icelandic law on annual accounts.

Our opinion is consistent with our additional report to the Audit Committee and Board of Directors.

The Consolidated Financial Statements comprise
- The Statement by the Board of Directors and President and CEO.
- The Consolidated Income Statement.
- The Consolidated Statement of Comprehensive Income.
- The Consolidated Balance Sheet.
- The Consolidated Statement of Cash Flow.
- The Consolidated Statement of Changes in Equity.
- Notes to the Consolidated Financial Statements, which include material accounting policies and other explanatory information.

The Statement by the Board of Directors and President and CEO and note 2. Quarterly statements are excluded from the audit, refer to section *reporting on other information*.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing. Our responsibilities under those standards are further described in the auditor’s responsibilities for the audit of the Consolidated Financial Statements section of our report.

Independence

We are independent of the Company in accordance with Icelandic laws on auditors and auditing and the code of ethics that apply to auditors in Iceland and relate to our audit of the Company's Consolidated Financial Statements. We have fulfilled our other ethical responsibilities in accordance with these requirements.

To the best of our knowledge and belief, we declare that non-audit services that we have provided to the Company are in accordance with the applicable law and regulations in Iceland and that we have not provided non-audit services that are prohibited under Article 5.1. of Regulation (EU) No. 537/2014.

The non-audit services that we have provided to the Company, in the period from 1 January 2025 to 31 December 2025, are disclosed in note no. 7 to the Consolidated Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independent Auditor´s Report

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Consolidated Financial Statements of the current period. These matters were addressed in the context of our audit of the Consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter
Impairment of goodwill

The book value of goodwill at year end 2025 amounted to USD 836 million.

The change in goodwill consists of additions due to current year business combinations amounting to USD 19 million together with exchange rate profits amounting to USD 41 million.

The carrying value of goodwill and the related impairment test relies on the discounted expected future cash flows (value in use) which are complex to determine and require significant estimation by management. The estimates used by management include the determination of market and sales potential, timing of product launches, profit margins, discount rate assumptions and the determination of appropriate cash generating units.

Due to the relative sensitivity of certain inputs to the impairment testing process, and in particular the future cash flows of the cash generating unit, the valuation of goodwill is considered to be a key audit matter.

We refer to note no. 40 that explains the impairment and Company's accounting policies in further detail. We also refer to note no. 13 on goodwill and note no. 33 relating to the change in the Company due to the acquisition of other companies.

Audit procedures
Our audit procedures included:

- Understanding management´s process for assessing the goodwill for potential impairment, including discussions with management for indications of impairment of goodwill.

- Evaluation of the reasonability of the model used by management to calculate the value in use of the individual cash generation units and if it complies with the requirements of IAS 36 Impairment of assets. This entailed involving our internal specialists to assist with the audit procedures carried out in relation to the impairment of goodwill.

- Understanding and validation of assumptions used to calculate the discount rates and value in use, including evaluation of price and volume forecast, long-term growth rates, and mathematical accuracy of relevant value-in-use models prepared by management.

- Performing sensitivity analysis based on activity and our understanding of the future prospects to identify whether these scenarios could give rise to an impairment.

- Evaluation of the presentation and disclosure of impairment testing, ensuring compliance with applicable accounting standards.

Reporting on other information, including the Statement by the Board of Directors and President and CEO

The Board of Directors and President and CEO are responsible for other information. The other information comprises of the Statement by the Board of Directors and President and CEO, note no. 2 Quarterly statements and the Annual Report, which we obtained prior to the date of this auditor's report.

Our opinion on the Consolidated Financial Statements does not cover the other information, including the Statement by the Board of Directors and President and CEO.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the Consolidated Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. In addition, in light of the knowledge and understanding of the entity and its environment obtained in the course of the audit, we are required to report if we have identified material misstatements in other information that we obtained prior to the date of this auditor's report. We have nothing to report in this respect.

Independent Auditor´s Report

With respect to the Statement by the Board of Directors and President and CEO we have, in accordance with article 104, of the Icelandic law on annual accounts reviewed that to the best of our knowledge, the Statement by the Board of Directors and President and CEO accompanying the Consolidated Financial Statements includes applicable information in accordance with Icelandic law on annual accounts if not presented elsewhere in the Consolidated Financial Statements.

Responsibilities of the Board of Directors and President and CEO

The Board of Directors and the President and CEO are responsible for the preparation and fair presentation of the Consolidated Financial Statements in accordance with IFRS accounting standards as adopted by the EU, and applicable articles in Icelandic law on annual accounts, and for such internal control as determined necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Company's management must provide appropriate explanations regarding its ability to continue as going concern, if applicable, and why management applies the presumption of going concern in the preparation and presentation of the Consolidated Financial Statements.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with International Standards on Auditing, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Independent Auditor´s Report

Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the Company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other legal and regulatory requirements

Report on European single electronic format (ESEF Regulation)

As part of our audit of the Consolidated Financial Statements of Embla Medical hf. we performed procedures to be able to issue an opinion on whether the Consolidated Financial Statements of Embla Medical hf. for the year 2025 with the file name EmblaMedical-2025-12-31.zip is prepared, in all material respects, in accordance with law no. 20/2021 Act on securities issuer obligations to issue information and self-report relating to requirements under the European single electronic format regulation EU no. 2019/815, which include requirements concerning preparation of the Consolidated Financial Statements in XHTML format and iXBRL markup.

The Board of Directors and President and CEO are responsible for preparing the Consolidated Financial Statements in accordance with law no. 20/2021. This responsibility includes preparing the Consolidated Financial Statements in a XHTML format in accordance to EU regulation no. 2019/815 on the European single electronic format (ESEF regulation).

Our responsibility is to obtain reasonable assurance, based on evidence that we have obtained, on whether the Consolidated Financial Statements are prepared in all material respects, in accordance with the ESEF Regulation, and to issue a report that includes our opinion. The nature, timing and extent of procedures selected depend on the auditor's judgement, including the assessment of the risks of material departures from the requirements set out in the ESEF regulation, whether due to fraud or error.

Independent Auditor´s Report

In our opinion, the Consolidated Financial Statements of Embla Medical hf. for the year 2025 with the file name EmblaMedical-2025-12-31.zip is prepared, in all material respects, in accordance with the European single electronic format regulation EU no. 2019/815.

Appointment

We were first appointed as auditors at the Company's annual general meeting on 8 March 2022. Our appointment has been renewed annually at the Company's annual general meeting representing a total period of uninterrupted engagement appointment of four years.

Reykjavík, 3 February 2026

PricewaterhouseCoopers ehf.

Vignir Rafn Gíslason
State Authorized Public Accountant

Ljósbrá Baldursdóttir
State Authorized Public Accountant

Consolidated Income Statement

All amounts in USD '000	Notes	2025	2024
Net sales	3	928,689	854,889
Cost of goods sold		(350,134)	(320,189)
Gross profit		**578,555**	**534,700**
Other income / (expenses)		608	399
Sales and marketing expenses		(334,180)	(311,151)
Research and development expenses		(45,856)	(40,832)
General and administrative expenses		(73,824)	(69,964)
Earnings before interest and tax (EBIT)		**125,303**	**113,153**
Financial income		2,061	3,251
Financial expenses		(21,115)	(24,746)
Net exchange rate difference		(4,974)	(4,435)
Net financial expenses	8	(24,028)	(25,930)
Share in net profit of associates	15	6,661	3,340
Earnings before tax (EBT)		**107,936**	**90,563**
Income tax	9	(24,291)	(21,603)
Net profit		**83,645**	**68,960**
Attributable to:			
Owners of the Company		83,336	68,278
Non-controlling interests		309	682
Net profit		**83,645**	**68,960**
Earnings per share	10		
Basic earnings per share (US cent)		19.6	16.2
Diluted earnings per share (US cent)		19.6	16.2

Consolidated Statement of Comprehensive Income

All amounts in USD '000	Notes	2025	2024
Net profit		83,645	68,960
Items that may be reclassified subsequently to income statement:			
Change in cash flow hedges	25	(1,826)	1,832
Fair value changes of financial liabilities		0	88
Exchange differences on translating foreign operations		22,721	(11,175)
Income tax	22	4,997	(2,073)
Other comprehensive income, net of income tax		**25,892**	**(11,328)**
Total comprehensive income		**109,537**	**57,632**
Attributable to:			
Owners of the Company		109,228	56,950
Non-controlling interests		309	682
Total comprehensive income		**109,537**	**57,632**

Consolidated Balance Sheet

Assets

All amounts in USD '000	Notes	31.12.2025	31.12.2024
Property, plant and equipment	11	80,215	71,824
Right of use assets	12	162,514	127,802
Goodwill	13	835,560	776,306
Other intangible assets	14	106,908	96,645
Investment in associates	15	27,950	20,364
Other financial assets	16	3,966	2,704
Deferred tax assets	27	55,380	46,365
Non-current assets		**1,272,493**	**1,142,010**
Inventories	17	165,617	143,102
Accounts receivable	18	144,782	121,915
Other financial assets	16	0	1,475
Other assets	19	45,092	44,300
Cash and cash equivalents	20	102,507	86,163
Current assets		**457,998**	**396,955**
Total assets		**1,730,491**	**1,538,965**

Consolidated Balance Sheet

Equity and liabilities

All amounts in USD '000	Notes	31.12.2025	31.12.2024
Issued capital and share premium	21	98,470	93,464
Other reserves	22	(50,494)	(75,390)
Retained earnings	23	842,572	759,112
Shareholders equity		890,549	777,186
Non-controlling interest		5,254	3,513
Total equity		**895,803**	**780,699**
Borrowings	26	292,174	328,754
Lease liabilities	12	153,499	118,279
Deferred tax liabilities	27	39,788	37,478
Provisions	28	8,723	7,937
Deferred income	29	11,346	8,589
Other financial liabilities	30	19,588	47,946
Non-current liabilities		**525,117**	**548,982**
Borrowings	26	67,678	28,620
Lease liabilities	12	28,218	24,136
Accounts payable		32,825	27,275
Income tax payable		21,322	18,305
Provisions	28	16,315	12,615
Accrued salaries and related expenses		59,550	48,715
Other financial liabilities	30	35,673	10,258
Other liabilities	32	47,989	39,361
Current liabilities		**309,571**	**209,284**
Total liabilities		**834,688**	**758,266**
Total equity and liabilities		**1,730,491**	**1,538,965**

Consolidated Statement of Cash Flow

All amounts in USD '000	Notes	2025	2024
Earnings before interests and tax (EBIT)		125,303	113,153
Depreciation, impairment and amortization	11, 12, 14	60,619	55,973
Change in inventories		(8,594)	(5,928)
Change in receivables		(12,321)	(5,524)
Change in payables		11,326	(2,279)
Change in provisions		3,858	3,174
Other operating activities		(2,403)	1,828
Cash generated from operations		**177,788**	**160,397**
Interest received		1,984	3,238
Interest paid		(20,551)	(24,082)
Income tax paid		(26,603)	(23,487)
Net cash generated from operating activities		**132,618**	**116,066**
Purchase of fixed and intangible assets	11, 14	(32,332)	(39,227)
Acquisition of subsidiaries, net of cash in acquired entities	33	(4,087)	(65,020)
Payment of contingent consideration and deferred payments		(10,603)	(5,052)
Dividend received	15	4,083	2,585
Other investing activities		(3,186)	1,944
Cash flows used in investing activities		**(46,126)**	**(104,770)**
Proceeds from long-term borrowings	26	57,463	0
Repayments of long-term borrowings	26	(59,011)	0
Changes in revolving credit facility	26	(30,823)	39,787
Payments of lease liabilities	12	(27,500)	(24,379)
Increase in subsidiaries not affecting control	23	(5,123)	(9,648)
Dividends from subsidiaries paid to non-controlling interests		(35)	0
Purchased treasury shares	21	(9,752)	0
Cash flows (used in) / generated from financing activities		**(74,782)**	**5,761**
Net change in cash		11,710	17,056
Exchange rate effects on cash held in foreign currencies		4,634	(3,545)
Cash and cash equivalents at beginning of period		86,163	72,653
Cash and cash equivalents at end of period		**102,507**	**86,163**

Non-cash financing and investing activities	20		

Consolidated Statement of Changes in Equity

All amounts in USD '000	Share capital	Share premium	Other reserves	Retained earnings	Share-holders equity	Non-controlling interests	Total equity
Balance at 1 January 2024	**4,781**	**61,479**	**(64,045)**	**699,667**	**701,883**	**3,123**	**705,005**
Net profit				68,278	**68,278**	682	**68,960**
Change in cash flow hedges			1,466		**1,466**		**1,466**
Fair value changes of financial liabilities			66		**66**		**66**
Transl. diff. of shares in subsidiaries			(12,860)		**(12,860)**		**(12,860)**
Total comprehensive income	0	0	(11,328)	68,278	**56,950**	682	**57,632**
Put option for minority share in subsidiary			689		**689**		**689**
Share contracts charge			602		**602**		**602**
Share contracts vested/expired			(1,308)	1,308	**0**		**0**
Issued new shares	48	27,156			**27,204**		**27,204**
Change in non-controlling interests				(10,142)	**(10,142)**	(292)	**(10,434)**
Balance at 31 December 2024	**4,829**	**88,635**	**(75,390)**	**759,112**	**777,186**	**3,513**	**780,699**
Net profit				83,336	**83,336**	309	**83,645**
Change in cash flow hedges			(1,461)		**(1,461)**		**(1,461)**
Transl. diff. of shares in subsidiaries			27,353		**27,353**		**27,353**
Total comprehensive income	0	0	25,892	83,336	**109,228**	309	**109,537**
Payment of dividends					**0**	(35)	**(35)**
Share contracts charge			1,970		**1,970**		**1,970**
Share contracts vested/expired		185	(2,967)	2,706	**(76)**		**(76)**
Purchase of treasury shares	(16)	(9,736)			**(9,752)**		**(9,752)**
Issued new shares	23	14,550			**14,573**		**14,573**
Minority interest arising on acquisition					**0**	4,611	**4,611**
Change in non-controlling interests				(2,581)	**(2,581)**	(3,143)	**(5,724)**
Balance at 31 December 2025	**4,836**	**93,634**	**(50,494)**	**842,572**	**890,549**	**5,254**	**895,803**

For details on other reserves refer to note 22.

In June 2016 the Icelandic Parliament passed a legal reform of the Icelandic Financial Statements Act no. 3/2006 which became effective on January 1, 2016. It requires retained earnings to be separated into two categories: restricted and unrestricted retained earnings. Profits, net of dividend, received from subsidiaries are classified as restricted retained earnings. The Company could, based on its control as the parent company, decide to let its subsidiaries pay dividends that would lower the restricted balance. As the Company has sufficient retained earnings from previous years, this legal act does not prevent the Company from making dividend payments to its shareholders.

Notes to the Consolidated Financial Statements

1. General information

Embla Medical is a limited liability company incorporated and domiciled in Iceland. The address of its registered office is Grjótháls 5, Reykjavík. Its ultimate controlling party is William Demant Invest A/S (WDI). The Consolidated Financial Statements of the Company as at and for the year ended 31 December 2025 comprise the Company and its subsidiaries (together referred to as "the Company" or "Embla Medical”).

The Company is a global orthopedics company, specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. Embla Medical also provides patient care through a global network of Orthotic and Prosthetic (O&P) facilities. The Company sells its products worldwide, but the principal markets are Europe and North America.

Embla Medical’s Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards (IFRS) accounting standards as adopted by the European Union and additional requirements in the Icelandic Annual Accounts Act no. 3/2006.

The Consolidated Financial Statements are presented in US dollars and all values are rounded to the nearest thousand (’000), except when otherwise indicated. This rounding may have impact on the total sum. In preparing the Consolidated Financial Statements, the Company has applied the concept of materiality to the presentation and level of disclosure. It is the opinion of management that essential and mandatory information is disclosed which is relevant to an understanding of these Consolidated Financial Statements.

These Consolidated Financial Statements have been approved for issue by the Board of Directors and President and CEO on 3 February 2026. The Consolidated Financial Statements as presented in this report are subject to approval by the Annual General Meeting of Shareholders, to be held on 10 March 2026.

The Company is listed on the Nasdaq Copenhagen Stock Exchange as EMBLA.

Notes to the Consolidated Financial Statements

2. Quarterly statements

		Unaudited			
	Full year 2025	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Net sales	928,689	256,691	236,795	232,418	202,786
Cost of goods sold	(350,134)	(98,625)	(88,559)	(87,931)	(75,020)
Gross profit	578,555	158,066	148,236	144,487	127,766
Gross profit margin	62%	62%	63%	62%	63%
Other income / (expenses)	608	175	(382)	447	367
Sales and marketing expenses	(334,180)	(92,194)	(81,400)	(82,529)	(78,057)
Research and development expenses	(45,856)	(11,948)	(11,489)	(11,851)	(10,569)
General and administrative expenses	(73,824)	(21,662)	(18,065)	(16,817)	(17,280)
EBIT	125,303	32,438	36,900	33,737	22,227
Net financial expenses	(24,028)	(2,947)	(4,135)	(9,764)	(7,181)
Share in net profit of associates	6,661	1,127	1,220	3,701	613
EBT	107,936	30,618	33,984	27,674	15,659
Income tax	(24,291)	(5,896)	(8,203)	(6,561)	(3,631)
Net profit	**83,645**	**24,722**	**25,782**	**21,113**	**12,027**
EBITDA	185,922	47,939	52,850	48,666	36,467
EBITDA margin	20%	19%	22%	21%	18%

There were no special items in the year 2025.

3. Net sales

	2025	2024
Sales by geographical segment:		
EMEA	457,445	394,869
Americas	398,516	392,898
APAC	72,728	67,122
Total	**928,689**	**854,889**
Sales by business segment:		
Prosthetics & Neuro Orthotics	513,408	451,306
Bracing & Supports	148,383	148,386
Internal product sales	(39,036)	(38,516)
External product sales	622,756	561,176
Patient Care	305,933	293,713
Total	**928,689**	**854,889**

Sales of additional sold warranties and service checks included in standard warranties are deferred at point of sale, then released over the warranty period. Refer to note 40 for accounting policy on revenue recognition and warranty provisions and refer to note 29 for breakdown of revenues recognized over time and amounts deferred and released during the year. All other revenues are recognized at point of sale.

Notes to the Consolidated Financial Statements

4. Segment information

The identified operating segments comprise the three main geographical markets. These segments are EMEA (Europe Middle-East and Africa), Americas and APAC (Asia-Pacific). The geographical segments form the basis for managerial decision making. Information reported to the President and CEO for the purposes of resource allocation and assessment of segment performance focuses on geographical markets.

No single customer accounted for more than 10% of the Company‘s sales in 2025 or 2024.

2025	EMEA	Americas	APAC	Eliminations	Consolidated
Sales					
External sales	457,445	398,516	72,728	0	928,689
Inter-segment sales	610,991	236,570	5,329	(852,890)	0
Total sales	1,068,436	635,086	78,057	(852,890)	928,689
Results					
Segment results (EBIT)	72,142	42,599	10,562	0	125,303
Net financial expenses					(24,028)
Share in net profit of associates					6,661
Earnings before tax (EBT)					107,936
Income tax					(24,291)
Net profit					**83,645**
Balance sheet 31.12.2025					
Segment assets	875,192	789,873	65,426	0	1,730,491
Segment liabilities	654,546	159,007	21,135	0	834,688

The total amount of non-current assets other than financial instruments and deferred tax assets, broken down by the Company´s country of domicile and other material location of the assets, is shown in the below table:

Country	2025	2024
USA	527,240	520,992
Germany	206,730	158,507
France	146,470	127,620
Iceland	114,486	104,081
Netherlands	36,724	21,934
Sweden	46,436	40,439
UK	43,968	42,619
Australia	19,244	18,742
Other	71,849	58,007
	1,213,147	**1,092,941**

Other information	EMEA	Americas	APAC	Eliminations	Consolidated
Capital additions	20,424	10,548	1,360	0	32,332
Depreciation, impairment and amortization	42,368	14,736	3,515	0	60,619

The majority of inter-segment sale prices are determined using the Transactional Net Margin Method (TNMM).

Notes to the Consolidated Financial Statements

2024	EMEA	Americas	APAC	Eliminations	Consolidated
Sales					
External sales	394,869	392,898	67,122	0	854,889
Inter-segment sales	509,552	160,128	4,955	(674,635)	0
Total sales	904,421	553,026	72,077	(674,635)	854,889
Results					
Segment results (EBIT)	61,253	44,033	7,866	0	113,153
Net financial income/(expenses)					(25,930)
Share in net profit of associates					3,340
Earnings before tax (EBT)					90,563
Income tax					(21,603)
Net profit					**68,960**
Balance sheet 31.12.2024					
Segment assets	719,241	759,915	59,809	0	1,538,965
Segment liabilities	581,549	158,382	18,335	0	758,266

Other information	EMEA	Americas	APAC	Eliminations	Consolidated
Capital additions	31,791	6,620	816	0	39,227
Depreciation, impairment and amortization	37,891	15,394	2,688	0	55,973

5. Sales and expenses split by main currencies

		2025			2024	
	LCY	USD	%	LCY	USD	%
Sales						
USD	358,545	358,545	39%	350,524	350,524	41%
EUR	251,970	285,142	31%	220,419	238,475	28%
ISK	562,783	4,391	1%	508,430	3,684	0%
SEK, NOK, DKK		107,189	12%		99,604	12%
GBP, AUD, CAD & Other		173,422	19%		162,603	19%
Total		**928,689**	**100%**		**854,889**	**100%**
COGS and OPEX						
USD	306,591	306,591	38%	302,848	302,848	41%
EUR	183,268	207,795	26%	164,563	178,000	24%
ISK	11,522,513	89,679	11%	11,112,364	80,541	11%
SEK, NOK, DKK		99,945	12%		91,609	12%
GBP, MXN, CAD & Other		99,376	12%		88,738	12%
Total		**803,386**	**100%**		**741,736**	**100%**

Currency split is derived by using best available information at each time.

Notes to the Consolidated Financial Statements

6. Salaries

	2025	2024
Salaries	299,437	280,540
Salary-related expenses	70,250	63,776
	369,687	**344,316**
Full time equivalent (FTE) on average	4,138	4,091
Full time equivalent at period end	4,192	4,078

Included in salary-related expense are pension related expenses amounting to USD 23 million (2024: USD 21.4 million). Information on share-based payments recognised in employee remuneration, are outlined in note 24 Share contracts.

Salaries and salary-related expenses, classified by functional category:

	2025	2024
Cost of goods sold	101,149	87,761
Sales and marketing expenses	197,593	192,302
Research and development expenses	28,390	24,873
General and administrative expenses	42,555	39,380
	369,687	**344,316**

Expenses related to information technology and human resource departments are allocated to the functions they support.

Management salaries and benefits

	Salaries		**Shares owned (ii)**	
Board of Directors:	**2025**	**2024**	**2025**	**2024**
Niels Jacobsen - Chairman of the Board(i)	114	111	219,493,992	219,493,992
Svafa Grönfeldt - Vice Chairman	76	74	0	0
Alberto Esquenazi	46	44	0	0
Arne Boye Nielsen	53	52	0	0
Caroline Vagner Rosenstand	46	44	0	0
Tina Abild Olesen	38	37	0	0

(i) Shares owned by William Demant Invest A/S which is represented by Niels Jacobsen on the Board. Niels Jacobsen and financially related parties own personally 203,330 shares (2024: 203,330 shares).
(ii) Shares owned are displayed in total number of owned shares, not rounded to the nearest thousand.

The Board of Directors did not hold any share option contracts at the end of the current period nor at the end of the comparative period.

Notes to the Consolidated Financial Statements

2025	Fixed base salary	Cash based incentive	Pension	Other benefits	Share based incentive	Total remuneration
Executive Management:						
Sveinn Sölvason, President and CEO(i)	745	223	133	24	276	1,400
Executive management (6.8 FTEs)(ii)	2,842	780	368	85	567	4,642
	3,587	**1,003**	**500**	**109**	**843**	**6,043**

2024	Fixed base salary	Cash based incentive	Pension	Other benefits	Share based incentive	Total remuneration
Executive Management:						
Sveinn Sölvason, President and CEO(i)	576	225	128	25	59	1,014
Executive management (6.6 FTEs)(ii)	2,558	814	368	41	418	4,199
	3,134	**1,040**	**496**	**66**	**477**	**5,213**

In February 2025 Conal Harte was appointed to the position of EVP of Patient Care and in April 2025, André Rocha joined the company as EVP of Research & Development, succeeding Hildur Einarsdóttir, who departed the company at the end of January 2025. Executive management is the same as key management.

(i) Shares owned at year end by Sveinn Sölvason 68,342 (2024: 68,342).

(ii) Shares owned at year end by executive management 83,406 (2024: 81,991).

7. Fees to auditors

	2025	2024
Audit of Financial Statements	1,681	1,664
Other services	122	90
	1,803	**1,754**

The table shows the fees to PricewaterhouseCoopers (PwC). In 2025, fees for other services amounting to USD 17 thousand were paid to PricewaterhouseCoopers ehf., the auditor of the Consolidated Financial Statements; no such fees were incurred in 2024.

8. Financial income / expenses

	2025	2024
Interests on bank deposits	1,523	1,966
Other financial income	539	1,285
Financial income	**2,061**	**3,251**
Interests on loans	(12,263)	(17,883)
Interest on leases	(7,261)	(5,365)
Other financial expenses	(1,591)	(1,499)
Financial expenses	**(21,115)**	**(24,746)**
Net exchange rate differences	(4,974)	(4,435)
Net financial expenses	**(24,028)**	**(25,930)**

Notes to the Consolidated Financial Statements

9. Income tax

	2025	2024
Current tax expenses	(29,926)	(29,456)
Deferred tax expenses	5,635	7,853
	(24,291)	**(21,603)**

	2025		2024	
	Amount	**%**	**Amount**	**%**
Earnings before tax	107,936		90,563	
Tax using Icelandic corporate tax rate	(21,587)	20%	(19,018)	21%
Difference between tax rates of non - Icelandic enterprises and Icelandic corporate tax rate	(2,588)	2%	(2,905)	3%
Impact of non-deductible expenses / non-taxable income	850	1%	92	(0%)
Impact of unrecognized tax assets, net	(473)	0%	(10)	0%
Other impacts	(492)	(1%)	238	(0%)
	(24,291)	**23%**	**(21,603)**	**24%**

Deferred tax expenses:	2025	2024
Origination and reversal of temporary differences	5,677	7,802
Effect of changes in tax rate	(42)	51
	5,635	**7,853**

For compliance and reporting on both Country-by-Country Reporting and Pillar Two, Embla Medical is part of WDI group. Embla Medical is not materially impacted by OECD’s/EUs Pillar Two Model Rules and local implementation thereof.

10. Earnings per share

	2025	2024
Net profit	83,645	68,960
Weighted average number of ordinary shares (in '000)	426,959	426,644
Adjustments for calculation of diluted earnings per share:		
Options and PSU/RSU	40	15
Weighted average number of shares including potential shares (in '000)	427,000	426,659
Basic earnings per share (US cent)	19.6	16.2
Diluted earnings per share (US cent)	19.6	16.2

Notes to the Consolidated Financial Statements

11. Property, plant and equipment

2025	Leasehold improvements	Machinery & equipment	Office equipment	Computer equipment	Total
Cost					
At 1 January	51,273	80,116	14,939	13,941	160,269
Additions	6,921	10,675	1,197	3,279	22,073
Business combinations	2,294	599	403	63	3,359
Eliminated on disposal	(46)	(178)	(21)	(130)	(375)
Fully depreciated assets	(94)	(522)	(189)	(2,224)	(3,029)
Exchange rate differences	2,399	1,539	1,534	833	6,304
At 31 December 2025	62,745	92,228	17,862	15,764	188,600
Depreciation					
At 1 January	19,654	50,499	9,850	8,442	88,445
Charge for the period	5,897	8,128	1,684	3,658	19,367
Eliminated on disposal	(23)	(183)	(19)	(106)	(331)
Fully depreciated assets	(94)	(522)	(189)	(2,224)	(3,029)
Exchange rate differences	1,652	888	849	545	3,935
At 31 December 2025	27,086	58,810	12,175	10,315	108,385
At 31 December 2025	**35,660**	**33,418**	**5,688**	**5,449**	**80,215**

Depreciation classified by functional category:	2025	2024
Cost of goods sold	9,739	9,850
Sales and marketing expenses	4,532	3,922
Research and development expenses	1,303	773
General and administrative expenses	3,793	4,030
Total	**19,367**	**18,575**

2024	Leasehold improvements	Machinery & equipment	Office equipment	Computer equipment	Total
Cost					
At 1 January	42,814	71,701	15,033	14,941	144,489
Additions	11,522	10,712	1,313	3,486	27,033
Business combinations	10	459	10	115	594
Eliminated on disposal	(27)	(224)	0	(180)	(431)
Fully depreciated assets	(1,086)	(1,540)	(871)	(3,867)	(7,364)
Exchange rate differences	(1,960)	(992)	(546)	(554)	(4,052)
At 31 December 2024	51,273	80,116	14,939	13,941	160,269
Depreciation					
At 1 January	17,284	44,462	9,431	8,926	80,103
Charge for the period	4,684	8,338	1,661	3,892	18,575
Eliminated on disposal	(14)	(144)	0	(155)	(313)
Fully depreciated assets	(1,086)	(1,540)	(871)	(3,867)	(7,364)
Exchange rate differences	(1,214)	(617)	(371)	(354)	(2,556)
At 31 December 2024	19,654	50,499	9,850	8,442	88,445
At 31 December 2024	**31,619**	**29,617**	**5,089**	**5,499**	**71,824**

None of the Company's property, plant and equipment are pledged as security. Major divestments are subject to bank approval.

Notes to the Consolidated Financial Statements

12. Leases

Right of use assets

2025	Buildings & sites	Machinery & equipment	Total
At 1 January	123,789	4,012	127,802
Additions and renewals	53,766	2,817	56,583
Depreciation charge and impairment for the period	(26,573)	(2,696)	(29,269)
Eliminated on disposal and termination	(2,790)	0	(2,790)
Exchange rate differences	9,664	524	10,188
At 31 December 2025	**157,857**	**4,658**	**162,514**

Depreciation and impairment classified by functional category:	2025	2024
Cost of goods sold	11,731	10,093
Sales and marketing expenses	9,161	5,047
Research and development expenses	3,149	3,028
General and administrative expenses	5,227	7,065
Total	**29,269**	**25,233**

2024	Buildings & sites	Machinery & equipment	Total
At 1 January	118,967	2,706	121,673
Additions and renewals	35,206	3,799	39,005
Depreciation charge for the period	(22,933)	(2,300)	(25,233)
Eliminated on disposal and termination	(1,649)	0	(1,649)
Exchange rate differences	(5,801)	(191)	(5,992)
At 31 December 2024	**123,789**	**4,012**	**127,802**

Lease liabilities

Contractual maturities analysis as follows:	31.12.2025	31.12.2024
In 2026 / 2025	35,227	29,307
In 2027 / 2026	31,089	24,831
In 2028 / 2027	26,456	20,438
In 2029 / 2028	21,763	16,985
Later	106,631	77,069
Total	**221,166**	**168,629**
Less: Present value discount	(39,450)	(26,214)
Lease liability	**181,716**	**142,415**
Lease liabilities are presented in the Consolidated Balance Sheet as follows:		
Non-Current	153,499	118,279
Current	28,218	24,136
Total	**181,716**	**142,415**

Lease related expenses recognized in the Consolidated Income Statement:	2025	2024
Depreciation expense from right of use assets	29,269	25,233
Interest expense on lease liabilities	7,261	5,365
Exchange difference on lease liabilities	1,562	2,209
Short-term and low value lease expenses not included in lease liabilities	563	677
Termination of right of use asset	112	76
Total	**38,766**	**33,560**

Total cash outflow for leases	34,761	29,743

Notes to the Consolidated Financial Statements

13. Goodwill

	2025	2024
At 1 January	776,306	690,855
Business combinations	18,698	104,489
Exchange rate differences	40,556	(19,038)
At 31 December	**835,560**	**776,306**

During the year, the Company determined the recoverable amount of goodwill and concluded that none of the Company's cash-generating units have suffered an impairment loss.

The carrying amount of goodwill was allocated to the following cash-generating units:

	31.12.2025	31.12.2024
Americas	453,848	451,947
EMEA	365,582	309,266
APAC	16,130	15,093
Total	**835,560**	**776,306**

The recoverable amount of the cash-generating units is determined based on a value in use calculation which require the use of assumption. The calculation use cash flow projections based on the financial forecast for the year 2026 approved by management and the Board of Directors.

Cash flow beyond the one-year period are extrapolated using the assumption stated below. Cash flows beyond 2030 have been extrapolated using a steady growth rate for all cash-generating units. This growth rate does not exceed the long-term average growth rate for the market in each segment. Management believes that any reasonable change in the key assumptions on which the recoverable amount is based would not cause the carrying amount to exceed its recoverable amount.

2025	Americas	EMEA	APAC
Sales growth (%)	7%	7%	12%
EBITDA margin (%)	20%	26%	16%
Capex ratio	3%	3%	4%
Perpetual growth rate (%)	2.5%	2.5%	2.5%
Pre-tax discount rate (%)	10.6%	10.2%	10.6%
Post-tax discount rate (%)	10.1%	9.7%	10.1%

2024	Americas	EMEA	APAC
Sales growth (%)	8%	8%	13%
EBITDA margin (%)	21%	25%	19%
Capex ratio	4%	3%	3%
Perpetual growth rate (%)	2.5%	2.5%	2.5%
Pre-tax discount rate (%)	10.6%	10.2%	10.6%
Post-tax discount rate (%)	10.2%	9.8%	10.1%

Notes to the Consolidated Financial Statements

Management has determined the values assigned to each of the above key assumptions as follows:

Sales growth
Average annual growth rate over the five-year forecast period is in line with current outlook, which is slightly reduced compared with the Growth'27 strategy approved by the Board of Directors.

EBITDA margin
Average annual EBITDA margin over the five-year forecast period based on gradual margin improvements in line with historical margin increases.

CAPEX ratio
Average annual amount of purchased fixed and intangible assets as ratio to sales. This is based on both historical and planned purchases and sales.

Perpetual growth rate
Average steady growth rate used to extrapolate cash flows beyond the forecast period. This growth rate does not exceed the long-term average growth rate for the market in each segment

Pre-tax discount rate
Reflect specific risk relating to the relevant segments and the countries in which they operate.

Post-tax discount rate (WACC)
Reflect specific risk relating to the relevant segments and the countries in which they operate, including tax effects based on effective tax rates in each segment.

Notes to the Consolidated Financial Statements

14. Other intangible assets

2025	Customer & distribution relationships	Patents & development costs	Trademarks	Software & other	Total
Cost					
At 1 January	36,701	32,214	8,156	63,175	140,246
Additions	0	960	39	1,409	2,408
Additions - internally generated	0	0	0	7,852	7,852
Business combinations	7,823	478	0	79	8,380
Fully amortized assets	0	0	(279)	(3,197)	(3,476)
Exchange rate differences	3,035	511	712	131	4,389
At 31 December 2025	47,559	34,163	8,627	69,448	159,798
Amortization					
At 1 January	9,393	9,789	523	23,896	43,601
Charge for the period	3,668	2,311	104	5,901	11,984
Fully amortized assets	0	0	(279)	(3,197)	(3,476)
Exchange rate differences	478	279	0	23	781
At 31 December 2025	13,540	12,379	348	26,623	52,889
At 31 December 2025	**34,019**	**21,784**	**8,280**	**42,825**	**106,908**

Amortization classified by functional category:	2025	2024
Cost of goods sold	883	1,577
Sales and marketing expenses	6,819	6,377
Research and development expenses	1,882	1,691
General and administrative expenses	2,400	2,520
Total	**11,984**	**12,165**

2024	Customer & distribution relationships	Patents & development costs	Trademarks	Software & other	Total
Cost					
At 1 January	34,254	28,343	2,871	54,246	119,714
Additions	55	1,716	79	1,612	3,462
Additions - internally generated	0	0	0	8,732	8,732
Business combinations	22,321	1,953	5,766	1,049	31,089
Fully amortized assets	(19,426)	(18)	(323)	(2,290)	(22,057)
Exchange rate differences	(503)	220	(237)	(174)	(694)
At 31 December 2024	36,701	32,214	8,156	63,175	140,246
Amortization					
At 1 January	25,676	7,780	588	19,829	53,873
Charge for the period	3,387	1,950	252	6,576	12,165
Fully amortized assets	(19,426)	(18)	(323)	(2,290)	(22,057)
Exchange rate differences	(244)	77	6	(219)	(380)
At 31 December 2024	9,393	9,789	523	23,896	43,601
At 31 December 2024	**27,308**	**22,425**	**7,633**	**39,279**	**96,645**

None of the Company's intangible assets are with restricted title or pledged as security.

Notes to the Consolidated Financial Statements

15. Investment in associates

	2025	2024
At 1 January	20,364	20,532
Additions	4,117	0
Share in net profit	6,661	3,340
Dividend received	(4,083)	(2,585)
Exchange rate differences	891	(923)
At 31 December	**27,950**	**20,364**

None of the individual associate´s financial information are material.

16. Other financial assets

	31.12.2025	31.12.2024
Financial asset at amortized cost:		
Unlisted securities	1,651	856
Restricted cash	609	534
Financial asset at fair value through Income Statement:		
Call option for shares in associates	1,706	1,315
Hedging derivatives:		
Cash flow hedge - foreign currency forwards	0	1,475
	3,966	**4,179**
Non-Current	3,966	2,704
Current	0	1,475
	3,966	**4,179**

Hedging derivatives are classified as other financial assets when the book value is positive and as other financial liabilities when book value is negative.

17. Inventories

	31.12.2025	31.12.2024
Raw material	52,460	44,268
Work in progress	30,618	23,167
Finished goods	82,539	75,667
	165,617	**143,102**

Inventories of USD 12.0 million (2024: USD 11.5 million) are expected to be sold or used in production after more than twelve months.

Inventories recognized as an expense during the period amounted to USD 286.7 million (2024: USD 260.6 million). Thereof USD 5.3 million (2024: USD 4.4 million) was recognized as an expense in respect of write-downs of inventory to net realizable value. There was no reversal of prior year write downs in the current year. The reserve for obsolete inventories at year end amounted to USD 6.8 million compared to USD 5.6 million in 2024.

None of the Company's inventories are pledged as security.

Notes to the Consolidated Financial Statements

18. Accounts receivable

	31.12.2025	31.12.2024
Nominal value	149,302	125,949
Allowance for doubtful accounts	(4,521)	(4,034)
	144,782	**121,915**

The average credit period on sale of goods are 47 days (2024: 43 days). An allowance has been made for doubtful accounts. This allowance has been determined by management with reference to the expected credit loss (ECL). Management considers that the carrying amount of receivables approximates their fair value.

Movement in the allowance for doubtful accounts	**2025**	**2024**
At 1 January	(4,034)	(5,076)
Impairment (losses)/gains recognized on receivables	(2,024)	372
Amounts written off as uncollectable	1,731	494
Exchange rate differences	(194)	176
At 31 December	**(4,521)**	**(4,034)**

	31.12.2025				
Accounts receivable	**Gross carrying amount at default**	**Expected credit loss rate**	**Collective allowance (lifetime ECL)**	**Individual allowance**	**Net carrying amount**
Not past due	95,498	0.1%	69	9	95,419
Less than six months past due	43,314	2.8%	1,195	310	41,809
Six to twelve months past due	4,000	12.5%	500	17	3,483
More than twelve months past due	6,490	19.5%	1,266	1,153	4,072
	149,302		**3,030**	**1,490**	**144,782**

	31.12.2024				
Accounts receivable	**Gross carrying amount at default**	**Expected credit loss rate**	**Collective allowance (lifetime ECL)**	**Individual allowance**	**Net carrying amount**
Not past due	81,684	0.1%	75	15	81,594
Less than six months past due	35,949	2.0%	722	429	34,798
Six to twelve months past due	2,755	17.1%	472	267	2,016
More than twelve months past due	5,561	27.4%	1,523	531	3,507
	125,949		**2,792**	**1,242**	**121,915**

The expected credit loss on accounts receivable is estimated using a provision matrix with reference to past default experience, general economic conditions and an assessment of both the current as well as expected conditions, including time value of money where appropriate. Individual allowances and adjustments to the collective bad debt provision are made based on the individual assessment of customers' situation and probability of incoming payments. Refer to note 40 for further details related to accounting policies.

The Company writes off accounts receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the debtor has been placed under liquidation or has entered into bankruptcy proceedings.

Notes to the Consolidated Financial Statements

19. Other assets

	31.12.2025	31.12.2024
Prepaid expenses	19,275	22,630
VAT refundable	8,758	7,361
Other	17,059	14,309
	45,092	**44,300**

The other line primarily includes accrued income, security deposits, various tax refunds and other short-term receivables.

20. Cash and cash equivalents

For the purpose of presentation in the Consolidated Statement of Cash Flow, cash and cash equivalents include bank balances, cash on hand and cash equivalents. Bank overdrafts are shown within borrowings in current liabilities in the Consolidated Balance Sheet.

Non-cash investing and financing activities

Non-cash investing and financing activities disclosed in other notes are:

- Exchange rate differences on borrowings and amortization of borrowing cost – note 26. Borrowings
- Liabilities acquired in Business Combinations – note 33. Business Combinations
- Assets acquired in Business Combinations – note 33. Business Combinations
- Deferred payments and contingent consideration on acquisitions – note 33. Business Combinations
- Additions to right of use assets and lease liabilities - note 12. Leases
- Exchange rate adjustment on lease liabilities - note 12. Leases
- Additions to financial assets and financial liabilities – notes 16. Other financial assets and 30. Other financial liabilities
- Fair value adjustment on financial assets and financial liabilities - notes 16. Other financial assets and 30. Other financial liabilities

Notes to the Consolidated Financial Statements

21. Issued capital and share premium

Common stock is as follows in thousands of shares in ISK:

	Issued shares	Treasury shares	Total
Balance at 1 January 2024	421,000	(701)	420,299
Issued shares	6,636		6,636
Balance at 31 December 2024	427,636	(701)	426,935
Issued shares	2,805		2,805
Sold treasury shares		15	15
Purchased treasury shares		(1,987)	(1,987)
Balance at 31 December 2025	**430,441**	**(2,673)**	**427,768**

Movement in issued capital is as follows in USD thousands:

	Share capital	Share premium	Total
Balance at 1 January 2024	4,781	61,479	66,260
Issued shares	48	27,156	27,204
Balance at 31 December 2024	4,829	88,635	93,464
Issued shares	23	14,550	14,573
Sold treasury shares	0	185	185
Purchased treasury shares	(16)	(9,736)	(9,752)
Balance at 31 December 2025	**4,836**	**93,634**	**98,470**

In 2025 the share buyback program was reinitiated. Decisions on share buybacks are made in accordance with the Company‘s Capital Structure and Capital Allocation Policy, within the authorizations granted by the Annual General Meeting. The share buyback programs are managed by Nordea, which make its trading decisions independently and without influence by the Company regarding the timing of the purchases. Share option contracts amounting to 15,078 Embla Medical hf shares were exercised during the year.

In 2025 in connection with the investment in a majority shares of Streifeneder ortho.production GmbH, new shares were issued raising the total share capital in nominal value by 0.7%, from ISK 427.6 million to ISK 430.4 million, resulting in USD 14.6 million share capital increase. At year end 2025 Embla Medical held 2.7 million treasury shares that equals to 0.6% of issued shares.

Notes to the Consolidated Financial Statements

22. Other reserves

The following table shows a breakdown of the movement in other reserves in the Consolidated Statement of Changes in Equity.

	Statutory reserve	Share contracts	Hedging	Financial assets	Currency Translation	Total
Balance at 1 January 2024	1,267	5,691	(258)	(755)	(69,990)	(64,045)
Change in cash flow hedges			1,832			1,832
Income tax			(366)			(366)
Fair value changes of financial liabilities				88		88
Income tax				(22)		(22)
Transl. diff. of shares in subsidiaries					(11,175)	(11,175)
Income tax					(1,685)	(1,685)
Total comprehensive income	0	0	1,466	66	(12,860)	(11,328)
Put option for minority share in subsidiary				689		689
Share contracts charge		602				602
Share contracts vested/expired		(1,308)				(1,308)
Balance at 31 December 2024	**1,267**	**4,985**	**1,208**	**0**	**(82,850)**	**(75,390)**
Change in cash flow hedges			(1,826)			(1,826)
Income tax			365			365
Transl. diff. of shares in subsidiaries					22,721	22,721
Income tax					4,632	4,632
Total comprehensive income	0	0	(1,461)	0	27,353	25,892
Share contracts charge		1,970				1,970
Share contracts vested/expired		(2,967)				(2,967)
Balance at 31 December 2025	**1,267**	**3,989**	**(253)**	**0**	**(55,497)**	**(50,494)**

Statutory reserve
The statutory reserve comprises certain portion of the share capital according to Icelandic Company Act.

Share contracts reserve
The share contracts reserve is used to recognize the fair value of options or share units issued to employees but not exercised, see note 24 for details.

Hedging reserve
The hedging reserve includes the cash flow hedge reserve and the costs of hedging reserve, see note 25 for details. The cash flow hedge reserve is used to recognize the effective portion of gains or losses on derivatives that are designated and qualify as cash flow hedges.

Currency translation reserve
The currency translation reserve comprises all currency differences arising from the translation of the financial statements of subsidiaries having different functional currencies than the Company as well as from the translation of liabilities that hedge net investment.

Notes to the Consolidated Financial Statements

23. Retained earnings

Transaction with non-controlling interests

During the year the Company acquired remaining shares in one of its subsidiary (2024 two). The effect on the equity attributable to the owners of the Company is as follows:

	2025	2024
Carrying amount of non-controlling interest acquired	3,143	292
Consideration paid to non-controlling interest	(5,123)	(9,648)
Contingent consideration	(600)	(786)
Excess of consideration paid recognized in retained earnings	(2,581)	(10,142)

24. Share contracts

In 2024 a new long term incentives program of performance share units ("PSUs") and restricted shares units ("RSUs") was initiated in accordance with approval at the Company's Annual General Meeting for 2023. This program replaced the previous share options plan.

Under this program management and key leaders can be rewarded for delivery of long-term strategy by granting PSUs for President and CEO and the Executive Management or RSUs for the Executive Management direct report at VP level and key specialists in strategic positions.

According to the program, if performance is on target, PSUs and RSUs will be granted each year based on the current Embla Medical share price and the current annual fixed salary of the participants. The maximum PSUs granted per year is approximately 375,000. The number of PSUs granted to the participants will follow the guidelines described in Embla Medical’s Remuneration Policy and will be reported in Embla Medical’s Remuneration Report. A maximum of 395,000 RSUs will be granted each year.

PSUs value at granting depends on performance and Embla’s share price. To calculate the PSUs/RSUs value at granting, the volume-weighted average share price on Nasdaq Copenhagen the first five trading days following the date of publication of Embla Medical’s Consolidated Financial Statements for the performance period/previous financial year is used. Performance metrics and targets are set at the beginning of the performance period. Performance metrics shall be closely aligned with Embla’s long-term strategy and sustainability and shall include a combination of financial, business and non-financial targets. At granting, the PSUs value is set within a defined range of the President and CEO’s fixed annual salary for the President and CEO, and within a separate defined range of fixed annual salary for other executives, with the specific amount determined according to their respective roles and responsibilities. RSU value is determined as a portion of the key employee’s fixed annual salary, set by the President and CEO based on the employee’s role and responsibilities. The potential value of the PSUs/RSUs at vesting depends on the share price development during the vesting time. The vesting time of the PSUs/RSUs is three years from granting. It is a vesting condition that the respective executive/key employee is employed by an Embla Medical entity at vesting, subject to certain good leaver provisions. At vesting, the PSUs/RSUs are converted into Embla Medical shares on a 1:1 ratio. For delivery of shares, the Board may either issue new shares (subject to the Annual General Meeting’s approval) or allow Embla Medical to use treasury shares that have been acquired based on authorization from the Annual General Meeting.

According to prior incentive plan (share options issued before 2024) where managers were granted options to purchase ordinary shares at an exercise price, determined by the average closing price of shares traded on the OMX Copenhagen stock exchange over the 20 trading days prior to the issue date. The employee must remain continuously employed with the Company until the option expiring date, either as an employee or in any other way, deemed satisfactory by the Company.

Each employee share option converts into one ordinary share on exercise. No amounts are paid or payable by the recipient to the Company on receipt of the option. The options carry neither right to dividends nor voting rights. The Company allows net settlement of options in which an equivalent number of shares are delivered to the employee that equals to the profit of the

Notes to the Consolidated Financial Statements

exercised options. With net settlement, the Company does not deliver in full the number of shares at exercise price. The fair value of the share options granted are valued using the Black-Scholes pricing model. Variables used in the Black-Scholes calculation are the exercise price per share, expected life in years, estimated volatility, annual rate of quarterly dividends and annual discount rate. Neither in 2025 nor in 2024, the expected volatility was not assumed nor the annual discount rate as new stock options were not granted. Expected life of options are three years and the options expire one year after the vesting date. If a share option vests during a closed period for insider trading the vesting period is automatically extended until the next open window for insider trading.

The following share PSU / RSU and share options contracts (hereinafter referred to as: share contracts) are outstanding at balance sheet date:

	Number of shares	Grant year	Exercise year	Exercise price (in DKK)	Share price at grant date (in DKK)	Weighted average remaining contr. life in months
Issued to Executive Management:						
PSU						
Sveinn Sölvason President and CEO	162,764	2024-2025	2027-2028		30.7-33.3	20
Executive management (6 persons)	406,936	2024-2025	2027-2028		30.7-33.3	20
Total	**569,700**					
Share options						
Sveinn Sölvason President and CEO	140,000	2022 - 2023	2025 - 2026	29.9-34.2	29.2-34.6	1
Executive management (4 persons)	400,000	2022	2025	28.5-41.7	29.5-44.0	0
Executive management (3 persons)	180,000	2023	2026	27.9-34.2	27.5-34.6	8
Total	**720,000**					
Issued to management team:						
RSU						
Managers (47 Persons)	667,334	2024-2025	2027-2028		30.7-32.2	21
Total	**667,334**					
Share options						
Managers (11 Persons)	410,000	2022	2025	28.5-41.7	29.5-44.0	0
Managers (1 person)	50,000	2023	2026	34.2	34.6	2
Total	**460,000**					
Total issued RSU/ PSU	**1,237,034**					**20**
Total issued share options	**1,180,000**					**1**
Total	**2,417,034**		**Total weighted average remain. contr. life in months**			**11**

Notes to the Consolidated Financial Statements

Movements in share options and RSU / PSU during the period:

	2025		2024	
	Number of shares	Weighted average exercise price (in DKK)	Number of shares	Weighted average exercise price (in DKK)
PSU / RSU				
Outstanding at 1 January	654,447		0	
Granted during period	592,693		699,700	
Forfeited during period	(10,106)		(45,253)	
Total outstanding at 31 December	**1,237,034**		**654,447**	
Share options				
Outstanding at 1 January	3,294,000	40.0	4,872,800	41.3
Expired during period	(1,824,000)	44.8	(741,200)	44.7
Forfeited during period	(75,000)	33.1	(837,600)	43.3
Exercised during period	(215,000)	31.0	0	0
Total outstanding at 31 December	**1,180,000**	**34.8**	**3,294,000**	**40.0**

In current year a total number of 215,000 share options were exercised on various dates. The weighted average share price at the dates of exercise amounted to DKK 35.2 per share.

The estimated remaining cost due to the share contracts and PSU/RSU is USD 4.5 million (2024: USD 2.5 million). An expense of USD 2.0 million (2024: USD 0.6 million) is recognized in the Consolidated Income Statement for the period. The exercise period of the share option contracts falls in 2026 and for RSU and PSU ranges from 2027 and 2028.

The range of the share price of exercised and expired options in the current year is DKK 28.5 to DKK 46.8 (2024: DKK 30.3 to DKK 46.3).

Embla's Medical yearly cost related to the new long-term incentive programs is estimated to be around USD 3.2 million when fully implemented.

Notes to the Consolidated Financial Statements

25. Hedging reserve

Embla Medical hedges its ISK and EUR exposure, using a twelve month, quarterly layered hedging strategy. This is done with forward currency contracts where Embla Medical sells EUR for ISK. At each balance sheet date Embla Medical has outstanding contracts covering approximately 50% of yearly ISK costs. Due to the layered approach, hedge ratio of closed contracts is approximately 80% of ISK costs. Embla Medical applies hedge accounting (IFRS 9) to the extent possible.

Movements in the hedging reserve during the period:

	2025	**2024**
At 1 January	1,208	(258)
Change in fair value of hedging instrument recognized in Other Comprehensive Income	(5,234)	308
Reclassified to Income Statement	3,408	1,524
Deferred tax	365	(366)
At 31 December	**(253)**	**1,208**

At balance sheet date ten forward contracts were open. The fair value of the contracts results in an liability of USD 0.4 million at year end 2025 (2024: 1.5 million asset). The effects of the foreign currency-related hedging instruments on the Company's financial position and performance are as follows:

	31.12.2025	**31.12.2024**
Carrying amount	352	(1,475)
Notional amount	55,136	36,545
Maturity date	Mar-Dec 26	Mar-Dec 25
Hedge ratio	1:1	1:1
Weighted average hedged rate for outstanding hedging instruments	149.2	153.8

Notes to the Consolidated Financial Statements

26. Borrowings

	31.12.2025	31.12.2024
Loans in USD	74,925	103,375
Loans In EUR	284,928	253,999
Total	**359,853**	**357,374**
Non-Current	292,174	328,754
Current	67,678	28,620
Total	**359,853**	**357,374**

Aggregated maturities of borrowings are as follows:

	31.12.2025	31.12.2024
In 2026 / 2025	67,678	28,620
In 2027 / 2026	238,626	51,224
In 2028 / 2027	10,651	277,530
In 2029 / 2028	10,641	0
Later	32,257	0
	359,853	**357,374**

The table below shows how cash and non-cash changes affect borrowings within the Company:

	2025	2024
At 1 January	357,374	333,335
Cash flows	(32,371)	39,787
Non-cash changes:		
Acquisition related	2,506	0
Exchange rate differences	31,790	(16,198)
Amortization of borrowing costs	555	450
At 31 December 2025	**359,853**	**357,374**

The weighted average interest on outstanding loans at 31.12.2025 was 2.5% (2024: 3.3%). The following table highlights key information of the Company´s borrowings:

Lender	Type	Currency	Interest type	Outstanding	Available
Nordic Investment Bank	Term, Bullet	EUR	Fixed	59,175	0
Nordic Investment Bank	Term, Amortizing	EUR	Floating	58,433	0
Nordea, Danske Bank	Revolver	EUR	Floating	157,857	35,272
European Investment Bank	Term, Bullet	USD	Fixed	74,925	0
Danske Bank	Overdraft	Multicurrency	Floating	9,463	78,716
Total				**359,853**	**113,988**

Notes to the Consolidated Financial Statements

27. Deferred tax assets / liabilities

	2025	2024
At 1 January	8,887	13,111
Income tax payable for the period	29,926	29,456
Calculated tax for the period	(24,291)	(21,603)
Business combinations	(2,435)	(9,995)
Recognized in other comprehensive income	3,674	(1,697)
Exchange rate differences	(169)	(385)
At 31 December	**15,592**	**8,887**
Deferred tax in the Balance Sheet:		
Deferred tax asset	55,380	46,365
Deferred tax liabilities	(39,788)	(37,478)
	15,592	**8,887**

Movement in deferred tax balances:

	1/1/2025	Recognized in Income Statement	Recognized directly in OCI	Other (i)	12/31/2025	Deferred tax assets	Deferred tax liabilities
Goodwill	(18,902)	(3,423)		(8)	(22,333)	4,228	(26,561)
Intangible assets	(16,657)	401		(3,471)	(19,727)	2,964	(22,691)
Property, plant and equipment	(1,870)	(327)		214	(1,983)	2,082	(4,065)
Tax loss carry forward	1,193	143		(43)	1,293	1,293	0
Inventories	19,227	6,382		3	25,612	26,424	(812)
Provisions	4,774	545		46	5,365	5,364	1
Current liabilities	16,745	969		225	17,939	19,363	(1,424)
Receivables	1,969	214		126	2,309	2,337	(28)
Other	2,408	731	3,674	305	7,118	7,197	(79)
Total	**8,887**	**5,635**	**3,674**	**(2,603)**	**15,592**	**71,252**	**(55,660)**
Deferred tax assets and liabilities offsetting						(15,872)	15,872
Net deferred tax assets (liabilities)						**55,380**	**(39,788)**

	1/1/2024	Recognized in Income Statement	Recognized directly in OCI	Other(i)	12/31/2024	Deferred tax assets	Deferred tax liabilities
Goodwill	(15,110)	(3,747)		(45)	(18,902)	4,240	(23,142)
Intangible assets	(8,899)	1,836		(9,594)	(16,657)	2,811	(19,468)
Property, plant and equipment	(1,946)	288		(212)	(1,870)	1,976	(3,846)
Tax loss carry forward	1,265	(7)		(65)	1,193	1,193	0
Inventories	15,972	3,257		(2)	19,227	20,040	(813)
Provisions	4,654	169		(49)	4,774	4,773	1
Current liabilities	11,842	4,981		(78)	16,745	17,890	(1,145)
Receivables	1,167	798		4	1,969	1,989	(20)
Other	4,166	279	(1,697)	(340)	2,408	3,490	(1,082)
Total	**13,111**	**7,853**	**(1,697)**	**(10,381)**	**8,887**	**58,402**	**(49,515)**
Deferred tax assets and liabilities offsetting						(12,037)	12,037
Net deferred tax assets (liabilities)						**46,365**	**(37,478)**

(i) Effects of foreign currency exchange rate differences and acquisitions.

The Company has unused tax losses available for which no deferred tax asset is recognized. At year end 2025 these unused tax losses amounted to USD 28.4 million (2024: USD 22.8 million). USD 12.9 million of this amount will expire in 5-10 years (2024: USD 8.4 million). The remaining tax losses carry an indefinite term.

Notes to the Consolidated Financial Statements

In relation to the elimination of intercompany gain in inventories, the Company has recognized a deferred tax benefit of USD 6.2 million (2024: USD 0.9 million) in the Consolidated Income Statement.

Embla Medical, as part of WDI group for Pillar Two reporting, has applied the exception to recognize deferred tax on OECD's/EU's Pillar Two Model Rules and local implementation hereof.

28. Provisions

2025	Warranty provisions	Restructuring provisions	Other provisions	Total
At 1 January	12,423	962	7,166	20,551
Additional provision recognized	11,722	700	3,645	16,067
Utilization of provision	(10,787)	(224)	(1,171)	(12,182)
Exchange rate differences	225	3	374	602
At 31 December 2025	**13,583**	**1,441**	**10,014**	**25,038**
Non-current	6,737	0	1,986	8,723
Current	6,846	1,441	8,028	16,315
At 31 December 2025	**13,583**	**1,441**	**10,014**	**25,038**

2024	Warranty provisions	Restructuring provisions	Other provisions	Total
At 1 January	10,789	2,777	4,422	17,988
Additional provision recognized	10,012	2,452	4,176	16,640
Utilization of provision	(8,225)	(4,267)	(1,077)	(13,569)
Exchange rate differences	(152)	0	(356)	(508)
At 31 December 2024	**12,423**	**962**	**7,166**	**20,551**
Non-current	6,290	0	1,647	7,937
Current	6,133	962	5,519	12,615
At 31 December 2024	**12,423**	**962**	**7,166**	**20,551**

Warranty provisions are expected to be utilized over the next 6 years in line with warranty terms. Restructuring provisions are expected to be utilized within the next 12 months as projects have been initialized but not all costs have materialized. Other provisions are related to various obligations of which USD 8.0 million are expected to be utilized within the next 12 months, the remaining amount in other provisions relate to employee long term services.

Notes to the Consolidated Financial Statements

29. Deferred income

	2025	2024
At 1 January	11,311	10,119
Deferred income	5,303	4,602
Released from deferred income	(3,110)	(2,962)
Exchange rate differences	851	(449)
At 31 December	**14,355**	**11,311**
Non-current	11,346	8,589
Current	3,009	2,722
At 31 December	**14,355**	**11,311**

Deferred income relates to the sale of additional warranty for prosthetic products and service checks included in standard warranty. Income from additional warranty is deferred when sold and released on a straight line basis within the warranty period. Income from service checks is deferred when sold and released when the service has been rendered. Additional warranties range from 2-6 years. The current deferred income is presented as part of other liabilities in the Consolidated Balance Sheet as indicated in note 32.

30. Other financial liabilities

	31.12.2025	31.12.2024
Financial liabilities at amortized cost:		
Deferred payments relating to business combinations	27,612	27,351
Other financial liabilities at amortized cost	212	381
Financial liabilities at fair value through Income Statement:		
Contingent considerations relating to business combinations	25,380	29,157
Put options for shares in associates	1,706	1,315
Hedging derivatives:		
Cash flow hedge - foreign currency forwards	352	0
	55,261	**58,204**
Non-current	19,588	47,946
Current	35,673	10,258
	55,261	**58,204**

Hedging derivatives are classified as other financial assets when the book value is positive and as other financial liabilities when book value is negative.

Contingent consideration relating to business combination is mainly resulting from acquisition of Streifeneder and Fior & Gentz. The contingent consideration payments for Streifeneder are dependent on savings and fair value is determined based on best information available at the date of acquisition. The full value of the contingent consideration relating to Streifeneder acquisition was accounted for at acquisition date and is payable in 2026. The payments related to Fior & Gentz acquisition can range up to 17 million USD based on management best estimate. The first payment was made this year. The remaining amount is payable in the years 2026 and 2027. The estimated payments are based on forecasted sales growth within the Company's sales channels. The earnout related to Naked Prosthetics acquisition was fully paid this year. The amount recognized at acquisition date for current year's acquisition can be found in note 33. Business combinations.

Put options for purchase of remaining shares in an associates are calculated as a multiple of EBITDA of the associates in the previous financial year in the proportion which the put option shares bear to the total shares of the entities. The options are exercisable in 2027 to 2033.

Notes to the Consolidated Financial Statements

31. Related party transactions

Balances and transactions within the Company (Embla Medical hf. and its subsidiaries) have been eliminated in consolidation and are not disclosed in this note.

The Company engages in transactions with some of its associated companies and other related parties. The transactions consist of sale and purchases where commercial terms and market prices apply.

Transactions and balances with related parties:

Associates	**2025**	**2024**
Sales of products	5,929	2,825
Purchases	5,313	4,695
Receivables from associates at 31 December	1,347	647
Payables to associates at 31 December	378	469
Other related parties	**2025**	**2024**
Sales of products	1,143	890
Purchases	7,135	6,850
Receivables from other related at 31 December	533	440
Payables to other related at 31 December	111	612

For disclosures relating to key management positions, refer to note 6.

32. Other liabilities

	31.12.2025	**31.12.2024**
Accrued expenses	25,105	23,033
Sales tax and VAT	6,861	4,979
Prepayments on orders	4,575	2,194
Sales return accrual	4,208	3,930
Deferred income	3,009	2,722
Other	4,231	2,503
	47,989	**39,361**

Notes to the Consolidated Financial Statements

33. Business combinations

On 17 July 2025 Embla Medical announced the acquisition of the majority share (51% of the shares) in the privately owned Streifeneder ortho.production GmbH (“Streifeneder”). The investment was completed on 29 August 2025 following regulatory approvals, hence four months of sales is included in the Consolidated Financial Statements for the year 2025 .

Streifeneder is an international developer and supplier of orthopaedic mobility solutions, employing around 100 people. In addition to its offerings of prosthetic and orthotic components, Streifeneder also supplies orthopaedic materials and equipment to the O&P industry. In 2024, Streifeneder realized sales of EUR 25 million (approximately USD 29m) with ~70% of sales related to prosthetics and orthopaedic materials. The majority of sales are generated in Germany, while also selling into other key European markets and distributing into the Americas and APAC regions.

As part of the consideration paid for Streifeneder, Embla Medical issued 2,805,135 new shares. The share price of each share was DKK 33.26, and the total value of the share price capital increase is thus DKK 93 million (EUR 12.5 million / USD 14.6 million).

A few other small acquisitions were made during the year.

Current year acquisitions were made to strengthen the Company´s product and service portfolios and our patient care business segment. The accounting for the acquisition was provisionally determined at the end of the reporting period. The goodwill is not deductible for income tax purpose.

In the Consolidated Income Statements for the year 2025, sales amounting to USD 11.8 million and net loss of USD 0.2 million were related to current year acquisitions.

The current year acquisitions took place in the middle of the year. If the acquisitions had occured on 1 January 2025, consolidated pro-forma results for the year ended 31 December 2025 would have been revenue of USD 29.4 million and net loss of USD 1.2 million.

Assets acquired and liabilities consumed at the date of acquisition:	**Total**
Property, plant and equipment	3,359
Other intangible assets	8,380
Other non-current assets	71
Inventories	6,029
Accounts and other receivables	392
Bank balances and cash equivalents	144
Borrowings	(2,506)
Deferred tax liabilities	(2,435)
Other liabilities	(3,978)
Non controlling interest	(4,611)
Net identifiable assets acquired	4,847
Goodwill	18,698
Net assets acquired	**23,545**

Consideration:	
Net assets acquired	23,545
Contingent consideration and deferred payments on current year´s acquisition	(4,740)
Issued new shares	(14,573)
Cash paid	4,232
Cash from acquired company	(144)
Consideration shown in Cash Flow	**4,087**

The split of property, plant and equipment and other intangible assets can be found in notes 11 and 14.

Notes to the Consolidated Financial Statements

34. Financial instruments

Financial assets and liabilities

The Company holds the following financial instruments:

Financial assets	Notes	31.12.2025	31.12.2024
Financial assets at amortized cost:			
Accounts receivable	18	144,782	121,915
Cash and cash equivalents	20	102,507	86,163
Financial assets at amortized cost	16	2,260	1,390
Financial assets at fair value through Income Statement	16	1,706	1,315
Hedging derivatives - foreign currency forwards	16	0	1,475
Total		**251,255**	**212,257**

Financial liabilities	Notes	31.12.2025	31.12.2024
Financial liabilities at amortized cost:			
Borrowings	26	359,853	357,374
Lease liabilities	12	181,716	142,415
Accounts payable		32,825	27,275
Other financial liabilities at amortized cost	30	27,824	27,732
Financial liabilities at fair value through Income Statement	30	27,086	30,472
Hedging derivatives - foreign currency forwards	30	352	0
Total		**629,656**	**585,267**

Fair value of financial instruments

In the above overview of financial instruments, financial assets and financial liabilities that are measured at fair value in the Consolidated Financial Statements can be identified.

Except as detailed in the following table, management considers that the carrying amount of financial assets and financial liabilities recognized in the Consolidated Financial Statements to approximate their fair value.

	31.12.2025		31.12.2024	
	Carrying amount	Fair value	Carrying amount	Fair value
Financial liabilities:				
Borrowings	359,853	358,553	357,374	358,808

The difference between the fair value and the carrying amount relates to distribution of borrowing cost and the difference between current market floating rates and the Company's rate on fixed rate loans. The fair value is determined as a level 3 in the fair value hierarchy.

Fair value hierarchy

The following table explains the judgements and estimates made in determining the fair values of the financial instruments recognized and measured at fair value in the Consolidated Financial Statements. In order to convey the reliability of the inputs used in determining the fair value, the Company has classified its financial instruments into the three levels prescribed under IFRS accounting standards as adopted by the European Union.

Notes to the Consolidated Financial Statements

Financial assets	Notes	Level 1	Level 2	Level 3	Total
Financial assets at fair value through income statement:					
Call option for shares in associates	16			1,706	1,706
Total financial assets		**0**	**0**	**1,706**	**1,706**

Financial liabilities	Notes	Level 1	Level 2	Level 3	Total
Financial liabilities at fair value through income statement:					
Contingent consideration related to acquisition	30			25,380	25,380
Put option for shares in associates	30			1,706	1,706
Hedging derivatives - foreign currency forwards	30		352		352
Total financial liabilities		**0**	**352**	**27,086**	**27,437**

There were no transfers between levels 1 and 2 for recurring fair value measurements during the year.

Level 1: The fair value of financial instruments traded in active markets is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Company is the current bid price.

Level 2: The fair value of financial instruments that are not traded in active markets is determined using valuation techniques that maximise the use of observable market data and rely as little as possible on entity-specific estimates.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

Capital risk management

The Company manages capital to ensure that the Company will be able to continue as a going concern while maximizing the return to stakeholders through the optimization of the debt and equity balance. The Company's overall strategy remains unchanged since 2024.

The capital structure of the Company consists of debt, which includes the borrowings disclosed in note 26, cash and cash equivalents and equity attributable to equity holders of the parent, comprising issued capital, reserves and retained earnings as disclosed in the Consolidated Statement of Changes in Equity.

Net interest bearing debt (NIBD) to EBITDA before special items ratio

The Company's management continuously reviews the capital structure. As a part of this review the management considers, amongst other the cost of capital and net debt to EBITDA before special items.

The NIBD to EBITDA before special items at period end was as follows:

	31.12.2025	31.12.2024
Net interest bearing debt	439,062	413,626
EBITDA before special items	185,922	173,264
Net interest bearing debt/EBITDA before special items	**2.4**	**2.4**

Notes to the Consolidated Financial Statements

Loan covenants

Under the terms of the Company borrowings, which has a carrying amount of USD 359.9 million (2024: USD 357.4 million) the Company is required to comply with the following financial covenants at the end of each annual and interim reporting period:

- Net debt (including deferred payments relating to business combinations) to EBITDA before special items should be below 4.0.

The Company is additionally required to comply with the following financial covenants at the end of each annual reporting period:

- The aggregate EBITDA of the Guarantors for the relevant reporting period represents not less than 50% of the Consolidated EBITDA of the Company.
- The aggregate gross assets of the Guarantors represents not less than 50% of the aggregate gross assets of the Company.

The Company has complied with these covenants throughout the reporting period. There are no indications that Embla Medical will have difficulties complying with the covenants in 2026.

Financial risk management objectives

The Company's corporate finance function provides services to the business, co-ordinates access to domestic and international financial markets, monitors and manages the financial risks relating to the operations of the Company. This is performed through internal risk reports which analyze exposures by degree and magnitude of risks. These risks include liquidity risk, interest rate risk, foreign currency exchange risk and counterparty credit risk.

The general policy is to apply natural hedging to the extent possible but Embla Medical also uses active hedging of currency exposure that is not covered by the natural hedge in sales and costs by currency. The use of financial derivatives is governed by the Company's policies approved by the Board of Directors, which provide written principles on foreign exchange risk, interest rate risk, credit risk, the use of financial derivatives and non-derivative financial instruments and the investment of excess liquidity. The Company does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

Currency risk management

The Company operates in a global market, hence exposure to exchange rate fluctuations arises. Exchange rate exposures are managed within approved policy parameters. The general policy is to apply natural exchange rate hedging to the extent possible.

Embla Medical hedges its ISK and EUR exposure, using a twelve month, quarterly layered hedging strategy. This is done with forward currency contracts where Embla Medical sells EUR for ISK. At each balance sheet date Embla Medical has outstanding contracts covering approximately 50% of yearly ISK costs. Due to the layered approach, hedge ratio of closed contracts is approximately 80% of ISK costs. At balance sheet date ten forward contracts were open. The fair value of the contracts results in a liability of USD 0.4 million at year end 2025 (2024: USD 1.5 million asset). Embla Medical applies hedge accounting (IFRS 9) to the extent possible. The carrying amounts of the Company's monetary assets and monetary liabilities denominated in currencies at the reporting date are as follows:

	Liabilities		Assets	
	31.12.2025	**31.12.2024**	**31.12.2025**	**31.12.2024**
EUR	374,280	308,727	72,532	41,818
USD	177,931	198,980	110,533	110,606
ISK	62,588	56,210	18,783	15,723
SEK	28,218	24,562	14,522	9,317
GBP	7,672	6,486	6,832	4,888
Other	52,567	38,478	73,145	72,730
	703,255	**633,444**	**296,346**	**255,082**

Notes to the Consolidated Financial Statements

Foreign currency sensitivity analysis

The Company is mainly exposed to the fluctuation of Icelandic krona (ISK) and Euro (EUR).

The following table details the Company's sensitivity to a 10% decrease in USD against the relevant foreign currencies with all other variables fixed. The sensitivity analysis includes all foreign currency denominated Income Statment items and adjusts their translation at the period end for a 10% change in foreign currency rates. The table below indicates the effect on net profit and equity where USD weakens 10% against the relevant currency. For a 10% strengthening of USD against the relevant currency, there would be an equal and opposite impact on the profit or loss and equity.

	EUR (i)		ISK (ii)	
	2025	**2024**	**2025**	**2024**
Net profit / Equity	7,176	5,656	(6,374)	(5,726)

(i) 26% (2024: 24%) of the Company's COGS and OPEX is in EUR against 31% (2024: 28%) of its sales causing an increase in profit if the USD decreases against the EUR.

(ii) 11% (2024: 11%) of the Company's COGS and OPEX is in ISK against 0.5% (2024: 0.4%) of its sales causing a decrease in profits if the USD decreases against the ISK.

Hedge accounting is not considered in the above calculation.

Interest rate risk management

The Company is exposed to interest rate risks as funds are borrowed at floating interest rates. Interest rate risk is managed by the Company´s treasury function and fixed rate loans or interest rate swap contracts may be used to maintain an appropriate mix between fixed and floating rate borrowings. At the end of 2025, 63% of total borrowings were on floating interest rates. Hedging activities are evaluated regularly to align with interest rate views and defined risk appetite and to ensure optimal hedging strategies are applied. The Company did not have any interest rate swap agreements outstanding at balance sheet date.

The Company's exposures to interest rates on financial assets and financial liabilities are detailed in the liquidity risk management section of this note.

Interest rate sensitivity analysis

The sensitivity analysis has been determined based on the exposure to interest rates on borrowings with floating terms. The analyses is prepared assuming the amount of liability outstanding at the reporting date was outstanding for the whole year. If interest rates had been 1 percent higher/lower and all other variables were held constant, the Company´s profit for the year ended 31 December 2025 would have decreased/increased by USD 2.3 million (2024: USD 2.3 million).

Notes to the Consolidated Financial Statements

Liquidity risk management

The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. At period end the Company had a total liquidity of USD 216.5 million, consisting of undrawn revolving credit facilities of USD 114.0 million (2024: USD 49.6 million) and cash and cash equivalents of USD 102.5 million (2024: USD 86.2 million).

The following tables detail the Company's remaining contractual maturity for its non-derivative financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to pay. The table includes both interest and principal cash flows.

	Weighted average effective interest	Less than 1 year	1-5 years	5+ years	Total
31.12.2025					
Borrowings	3.2%	79,794	296,726	11,012	387,532
Lease liabilities	4.5%	35,227	114,325	71,615	221,166
Non-interest bearing liabilities	-	175,615	17,001	0	192,616
		290,636	**428,051**	**82,627**	**801,314**
31.12.2024					
Borrowings	4.5%	45,178	356,973	0	402,151
Lease liabilities	4.0%	29,307	86,347	52,975	168,629
Non-interest bearing liabilities	-	122,887	47,972	0	170,859
		197,372	**491,292**	**52,975**	**741,639**

Credit risk management

The Company manages the financial counterparty credit risk centrally. Primary Banks should have a long-term credit rating of at least A-/A3 and a short-term credit rating of at least A-2/P-2. Other financial counterparties should have investment grade credit ratings.

Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables.

Accounts receivable consist of a large number of customers spread across geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable. Refer to note 18 for assessment of expected credit loss (ECL) and accounting policy on impairment of financial assets.

The Company is exposed to normal business risk in collecting accounts receivable. Adequate allowance is made for bad debt in line with the Company accounting policy.

Book value of financial assets measured at amortized cost represents the maximum exposure to credit risk.

Notes to the Consolidated Financial Statements

35. The Consolidation

Information about the main composition of Embla Medical hf. and its subsidiaries at the end of the reporting period is as follows:

Name of company	Place of registration and operation	Ownership %	Principal activity
Össur Americas Inc	USA	100%	Sales, R&D, distribution and manufacturer
Össur Australia PTY Ltd	Australia	100%	Sales, distribution and services
Össur Canada Inc	Canada	100%	Sales, distribution and services
Össur Deutschland GmbH	Germany	100%	Sales, distribution and services
Össur Europe BV	Netherlands	100%	Sales, distribution and services
Össur France Sarl	France	100%	Sales, distribution and services
Össur Iceland ehf	Iceland	100%	R&D and manufacturer
Össur UK Ltd	UK	100%	Sales, distribution and services
ForMotion Australia PTY Ltd	Australia	100%	Patient Care
College Park Industries, Inc	USA	100%	Sales, R&D, distribution and manufacturer
Fior & Gentz GmbH	Germany	100%	Sales, distribution and manufacturer
ForMotion Sweden AB	Sweden	100%	Patient Care
ForMotion Norway AS	Norway	100%	Patient Care
Touch Bionics Ltd	UK	100%	Manufacturer and R&D

Notes to the Consolidated Financial Statements

36. Other information

The Company is required to file the primary statements of the Consolidated Financial Statements in the new European Single Electronic Format (ESEF) and therefore those statements are prepared in the XHTML format that can be displayed in a standard browser. The primary statements in the Consolidated Financial Statements are tagged using inline eXtensible Business Reporting Language (iXBRL). The iXBRL tags comply with the ESEF taxonomy, which is included in the ESEF Regulation and developed based on the IFRS taxonomy published by the IFRS Foundation. Where a primary statements line item is not defined in the ESEF taxonomy, an extension to the taxonomy has been created. Extensions are anchored to elements in the ESEF taxonomy, except for extensions which are subtotals. The Consolidated Financial Statements submitted to the Icelandic Financial Supervisory Authority consists of the XHTML document together with certain technical files, all included in a file named “EmblaMedical-2025-12-31.zip”.

37. Insurance

	31.12.2025		31.12.2024	
	Insurance value	Book value	Insurance value	Book value
Fixed assets and inventories	261,754	252,613	239,336	220,478

The book value of fixed assets and inventories is adjusted for inventory reserve. The Company has purchased a Property Damage & Business Interruption insurance intended to compensate for damages on owned property and temporary loss of income due to such loss. Additionally, the Company has numerous insurances in place that are necessary to insure against the risks to its operations, including but not limited to general and product liability, professional liability, product recall insurance, directors’ and officers’ liability and certain types of frauds towards the Company.

38. Contingent liabilities

Embla Medical has committed to a three-year program designed to deliver high-quality prosthetic care and rehabilitation to up to 1,000 Ukrainian amputees. With a total estimated value of USD 11 million over three years, the new initiative will be co-financed by the Government of Iceland (USD 3.9 million) and Embla Medical (USD 7.7 million). As of year-end, Embla Medical’s remaining financial commitment totals USD 7.0 million, which will be recognized as expense in proportion to the number of amputees served over the coming three-year period.

The Company is engaged in certain litigation proceedings and various ongoing audits and investigations. Management, on an ongoing basis, assesses the possible financial impact of current and pending litigations. Relevant information is disclosed when management is able to assess whether a litigation could potentially have a material financial impact on the Company. In the opinion of management there are currently no litigations expected to have a material effect on the Company's financial position, operating profit or cash flow.

Notes to the Consolidated Financial Statements

39. Adoption of new and revised standards

New and amended IFRS that are effective for the current year

The following amendment to IFRS became mandatorily effective in the current year. The application of the below amendment has no effect on the Consolidated Financial Statements:

Amendments to IAS 21: Lack of Exchangeability.

New and revised IFRS in issue but not yet effective

At the date of authorization of these Consolidated Financial Statements, the Company has not applied new and revised IFRS that have been issued but are not yet effective.

Management of the Company does not expect that the adoption of the standards will have a material impact on the Financial Statements of the Company in future periods.

Management has performed an initial assessment of the impact of IFRS 18 on the Consolidated Financial Statements. Since IFRS 18 does not change recognition or measurement requirements, but focuses on presentation and disclosure, the implementation is not expected to have a significant impact on the Company’s overall reported financial position or performance. Rather, the impact will primarily be related to the classification and presentation changes within the statement of profit or loss, enhanced disaggregation in the statement of financial position and notes, as well as the introduction of management-defined performance measures. Based on the analysis performed, the Company does not anticipate any material adjustments to the amounts presented in the Consolidated Financial Statements that would be required by IFRS 18. Work is ongoing to update internal reporting structures to comply with the new presentation and disclosure requirements by the effective date. IFRS 18 becomes effective for annual reporting periods beginning on or after 1 January 2027.

Standards on sustainability, IFRS S1 and IFRS S2 are not impacting EU companies as separate legislation applies to EU companies (ESRS). The European Sustainability Reporting Standards (ESRS) will likely become effective in 2026 for the Company depending on when approved by Icelandic authorities.

Notes to the Consolidated Financial Statements

40. Summary of material accounting policies

Statement of compliance

The Consolidated Financial Statements have been prepared in accordance with IFRS accounting standards as adopted by the European Union and additional requirements in the Icelandic Annual Accounts Act no. 3/2006.

Basis of preparation

The Consolidated Financial Statements have been prepared under the historical cost basis except for certain financial instruments that are measured at fair values. Historical cost is generally based on the fair value of the consideration given in exchange for assets. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company considers the characteristics of the asset or liability as market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these Consolidated Financial Statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2 and measurements that have some similarities to fair value but are not fair value, such as net realizable value of inventories in IAS 2 or value of assets in use in IAS 36.

Basis of consolidation

The Consolidated Financial Statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and
- can use its power to affect its returns.

The Company reassesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether the Company's voting rights in an investee are sufficient to give it power, including:

- the size of the Company's holding of voting rights relative to the size and dispersion of holdings of the other vote holders;
- potential voting rights held by the Company, other vote holders or other parties;
- rights arising from other contractual arrangements; and
- any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders' meetings.

Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date that control ceases. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Company's accounting policies. All intercompany assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Company are eliminated in full on consolidation.

Notes to the Consolidated Financial Statements

Put options over non-controlling interest are recognized as financial liabilities at the present value of the estimated exercise price. The initial carrying amount is charged against equity attributable to owners of the parent, and subsequent remeasurement of the liability are recognized accordingly. The Company treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Company. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized directly in equity attributable to owners of the Company.

Business combinations

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combinations is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition-related costs are recognized in profit or loss as incurred.

The acquiree's identifiable assets, liabilities and contingent liabilities that meet the conditions for recognition under IFRS 3 are recognized at their fair value at the acquisition date, except that:

- deferred tax assets or liabilities and liabilities or assets related to employee benefit arrangements are recognized and measured in accordance with IAS 12 Income Taxes and IAS 19 Employee Benefits respectively;
- liabilities or equity instruments related to share-based payment arrangements of the acquiree or share-based payment arrangements of the Company entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 Share-based Payment at the acquisition date; and
- assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations are measured in accordance with that standard.

Goodwill arising on acquisition is recognized as an asset and initially measured at cost, being the excess of the purchase price of the business combinations over the Company's interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree. If, after reassessment, the Company's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities exceeds the cost of the business combinations, the excess is recognized immediately in profit or loss. Non-controlling interests that present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured either at fair value or at the non-controlling interests' proportionate share of the recognized amounts of the acquiree's identifiable net assets. The choice of measurement basis is made on a transaction-by-transaction basis. Other types of non-controlling interests are measured at fair value or, when applicable, on the basis specified in another IFRS.

When the consideration transferred by the Company in a business combinations includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combinations. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ about facts and circumstances that existed at the acquisition date.

The subsequent accounting for changes in the fair value of the contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IFRS 9 with the corresponding gain or loss being recognized in profit or loss.

If the initial accounting for a business combinations is incomplete by the end of the reporting period in which the combination occurs, the Company reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or additional assets or liabilities are recognized, to reflect new information obtained

Notes to the Consolidated Financial Statements

about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date.

When a business combinations is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date (i.e., the date when the Company obtains control) and the resulting gain or loss, if any, is recognized in profit or loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to profit or loss where such treatment would be appropriate if that interest were disposed of.

The measurement period is the period from the date of acquisition to the date the Company obtains complete information about facts and circumstances that existed as of the acquisition date and is subject to a maximum of one year.

Investments in associates

An associate is an entity over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not in control or joint control over those policies.

The profit and losses, assets and liabilities of associates are incorporated in the Consolidated Financial Statements using the equity method of accounting. Under the equity method, investments in associates are initially recognized in the balance sheet and adjusted for post-acquisition changes in the Company's share of the net assets of the associate, less any impairment in the value of individual investments. Dividends received or receivable from associates are recognized as a reduction in the carrying amount of the investment. Where the Company´s share of losses in associates equals or exceeds its interest in the associate, the Company does not recognize further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.

The requirements of IAS 36 Impairment of Assets are applied to determine whether it is necessary to recognize any impairment loss with respect to the Company's investment in an associate. When necessary, the entire carrying amount of the investment (including goodwill) is tested for impairment in accordance with the standard as a single asset by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount. Any impairment loss recognized forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognized in accordance with IAS 36 to the extent that the recoverable amount of the investment subsequently increases.

Upon loss of significant influence over the associate, the Company measures and recognizes any retained investment at its fair value. Any difference between the carrying amount of the associate upon loss of significant influence and the fair value of the retained investment and proceeds from disposal is recognized in profit or loss.

Goodwill

Goodwill is initially recognized as an asset at the excess of the purchase price of the business combinations over the Company's interest in the net fair value of the identifiable assets, liabilities, contingent liabilities, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree.

Goodwill is not amortized but recognized at cost less accumulated impairment losses. For impairment testing, goodwill is allocated to each of the Company's cash-generating units (CGU) expected to benefit from the synergies of the combination. CGU’s to which goodwill has been allocated are tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. When performing the impairment test, the recoverable amount of the CGU is determined. The value in use is calculated as the present value of expected future cash flows from the CGU. If the recoverable amount of the CGU is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. Impairment loss for goodwill is recognized directly in profit or loss in the Consolidated Income Statement. The carrying amount of goodwill is tested for impairment together with the other non-current assets in the CGU to which goodwill is allocated to. Impairment of goodwill is not reversed in a subsequent period.

Notes to the Consolidated Financial Statements

Consistent with the Company's management and reporting structure, the lowest level of CGU's is the individual geographical segment, as cash inflows are generated largely independent of cash inflow in other geographical segments within the Company. Accordingly, impairment tests are carried out per geographical segment, and goodwill and other intangibles are allocated to these CGU's.

On disposal of the relevant CGU, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

The Company's policy for goodwill arising on the acquisition of an associate is described in the accounting policy for Investments in associates above.

Revenue recognition

Revenue is measured at the transaction price of the consideration received or receivable. Revenue is reduced for estimated customer returns, rebates and other similar allowances.

Sale of goods and services

The Company sells bracing & support products, prosthetics & neuro orthotics products, and related services both as wholesaler and directly to customers through its own distribution channels.

Revenue for the sale of products including standard warranty is recognized when control of the goods has transferred. Control is considered transferred when the goods have been shipped or directly delivered to retail customer. Following shipment, it is considered that our customers have full discretion over the manner of distribution and price to sell the goods. They hold the primary responsibility when selling the goods, and bear the risks of obsolescence and loss in relation to the goods. A receivable is recognized by the Company when the goods are shipped to the customer as this represents the point in time at which the right to consideration becomes unconditional, as only the passage of time is required before payment is due. General payment terms in the Company´s main markets is 30 days.

Sales related standard warranties serve as an assurance that the products sold comply with agreed-upon specifications, those warranties are accounted for in accordance with IAS 37 Provisions. For some prosthetics products, a service check is included in the standard warranty and is treated as a distinct service and is accounted for as a separate performance obligation. The customer has an option to purchase an additional warranty, which is treated as a distinct service as the Company promises to provide the service to the customer in addition to the product and the standard warranty. That warranty is accounted for as a separate performance obligation.

Revenues from the sale of additional warranties are deferred when sold and released on a straight-line basis within the warranty period. Revenues from service checks included in the standard warranty are deferred when sold and released when the service has been rendered or the service obligation has ended. Deferred revenues are shown separately within liabilities in the balance sheet.

Under the Company's standard contract terms, customers have a right of return within 30-90 days. At the point of sale, a refund liability and a corresponding adjustment to revenue is recognized for those products expected to be returned. The Company uses its accumulated historical experience to estimate the number of returns on a portfolio level using the expected value method. It is considered highly unlikely that a significant reversal in the cumulative revenue recognized will occur given the consistent level of returns over previous years.

Interest revenue and dividend

Interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts

Notes to the Consolidated Financial Statements

through the expected life of the financial asset to that asset's net carrying amount on initial recognition. Dividend income from investments is recognized when the shareholder's right to receive payment has been established.

Leases

The Company leases office buildings, manufacturing and warehouse facilities and vehicles. Rental contracts are typically made for fixed periods but may have extension options, exercisable by the Company. In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option. Extension options are only included in the lease term if the lease is reasonably certain to be extended. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions.

The Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognizes a right of use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease, unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right of use asset in a similar economic environment, with similar terms, security and conditions.

To determine the incremental borrowing rate, the Company uses a build-up approach that begins with a risk-free interest rate. The rate is then adjusted for credit risk for leases held by the Company and further modified based on specific lease factors such as term, country and currency.

The lease payments incorporated in the measurement of the lease liability includes fixed payments less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees, and the exercise price of purchase options if the Company expects to exercise the option.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The Company remeasures the lease liability if the lease term has changed, when lease payments changes in an index or rate or when a lease contract is modified, and the modification is not accounted for as a separate lease.

Right of use asset is initially measured at the amount equal to the initial measurement of lease liability. Right of use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

Variable rents that depend on usage are not included in the measurement of the lease liability and the right of use asset. The related payments are recognized as an expense in the period in which the event or condition that triggers those payments occurs.

As a practical expedient, IFRS 16 permits a lessee not to separate non-lease components, and instead account for any lease and associated non-lease components as a single arrangement. The Company has used this practical expedient.

Notes to the Consolidated Financial Statements

Foreign currencies

Functional and presentation currency

Items included in the financial statements of each of the group's entities are measured using the currency of the primary economic environment in which the entity operates, the functional currency. The Consolidated Financial Statements are presented in USD, which is the Company´s reporting currency and the functional currency of Embla Medical hf.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, and from the translation of monetary assets and liabilities denominated in foreign currencies at 31 December 2025 exchange rates, are generally recognized in income statement.

Foreign subsidiaries

The income statement and balance sheet of foreign subsidiaries that have a functional currency different from the Company's presentation currency are translated into the presentation currency as follows:

- assets and liabilities are translated at the closing rate at balance sheet date,
- income and expenses for income statement and statement of comprehensive income are translated at average exchange rates, and
- all resulting exchange differences are recognized in other comprehensive income.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.

Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate as per 31 December 2025.

Share capital

The share capital of Embla Medical at balance sheet date is ISK 430,441,257 nominal value, divided into the same number of shares. There is only one class of shares, and all shares carry one vote, besides treasury shares that do not carry voting rights.

Share premium

The share premium reserve is comprised of payments in excess of nominal value of ISK 1 per share that shareholders have paid for shares sold by the Company.

Share-based payments

Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled share-based transactions are set out in note 24.

The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Company's estimate of equity instruments that will eventually vest, with a corresponding increase

Notes to the Consolidated Financial Statements

in equity. At the end of each reporting period, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity-settled employee benefits reserve.

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the period. Taxable profit differs from net profit as reported in the Consolidated Income Statement because it excludes items of income or expense that are taxable or deductible in other periods and it further excludes items that are never taxable or deductible. The Company's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the Consolidated Financial Statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from goodwill or from the initial recognition (other than in a business combinations) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognized for taxable temporary differences associated with investments in subsidiaries, except where the Company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognized to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.
The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

In the preparation of the Consolidated Financial Statements, accumulated gains in inventories from intercompany transactions are eliminated. This influences the income tax expenses of the consolidated companies, and an adjustment is included in the deferred tax asset. Income tax expense is calculated in accordance with tax rates in the countries where the inventories are purchased.

Embla Medical, as a part of William Demant Invest A/S group for Pillar Two reporting, has applied the temporary exception, introduced in May 2023, from the accounting requirements for deferred taxes in IAS 12, so that the group neither recognizes nor discloses information about deferred tax assets and liabilities related to Pillar Two income taxes.

Notes to the Consolidated Financial Statements

Current and deferred tax for the year

Current and deferred tax are recognized in profit or loss, except when they relate to items that are recognized in Other Comprehensive Income or directly in equity, in which case, the current and deferred tax are also recognized in Other Comprehensive Income or directly in equity respectively. Where current tax or deferred tax arises from the initial accounting for a business combinations, the tax effect is included in the accounting for the business combinations.

Property, plant and equipment

Property, plant and equipment are recognized as an asset when it is probable that future economic benefits associated with the asset will flow to the Company and the cost of the asset can be measured in a reliable manner.

Property, plant and equipment which qualify for recognition as an asset are initially measured at cost. The cost of a property, plant and equipment comprises its purchase price and any directly attributable cost of bringing the asset to working condition for its intended use.

The depreciable amount of the asset is allocated on a straight-line basis over its useful life. The depreciation charge for each period is recognized as an expense. The estimated useful lives, residual values and depreciation method are reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis.

The following useful lives are used in the calculation of depreciation:

Machinery and equipment	3-10 years
Office equipment	5-8 years
Computer equipment	2-5 years

Leasehold improvements are depreciated over the lease term.

The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset at the date of the sale transaction and is recognized in the Consolidated Income Statement.

Intangible assets

Intangible assets acquired separately

Intangible assets with finite useful life are reported at cost less accumulated amortization and accumulated impairment losses. Amortization is allocated on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each balance sheet date, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives are carried at cost less accumulated impairment losses.

The following useful lives are used in the calculation of amortization:

Customer and distribution relationships	4-10 years
Patents and development costs	5-50 years
Trademarks	3-infinitive
Software and other	2-10 years

Internally generated intangible assets

Expenditure on research activities is recognized as an expense in the period in which it is incurred.

An internally generated intangible asset arising from the Company's development is recognized only if all of the following conditions are met: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the

Notes to the Consolidated Financial Statements

intention to complete the intangible asset and use or sell it; the ability to use or sell the intangible asset; the intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset and the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognized for internally generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where internally generated intangible asset cannot be recognized, development expenditure is charged to profit or loss in the period in which it is incurred. Majority of development expenditure is expensed in the period in which it is incurred except for certain projects.

After initial recognition, internally generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets acquired separately.

Intangible assets acquired in a business combinations

Intangible assets acquired in a business combinations are identified and recognized separately from goodwill where they satisfy the definition of an intangible asset, and their fair values can be measured reliably. The cost of such intangible assets is their fair value at the acquisition date.

After initial recognition, intangible assets acquired in a business combinations are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets acquired separately.

Derecognition of intangible assets

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized.

Impairment of tangible and intangible assets excluding goodwill

At each balance sheet date, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit (CGU) to which the asset belongs. Where a reasonable and consistent basis of allocation can be identified, assets are also allocated to individual CGU, or otherwise they are allocated to the smallest group of CGU's for which a reasonable and consistent allocation basis can be identified.

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (CGU) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, deposits with banks and deposits with financial institutions. Bank overdrafts are shown within borrowings in current liabilities in the Consolidated Balance Sheet. Deposits that are subject to regulatory

Notes to the Consolidated Financial Statements

restrictions and are therefore not available for general use by the Company are presented as restricted cash and disclosed in note 16.

Inventories

Inventories are stated at the lower of cost and net realizable value. Costs, including an appropriate portion of fixed and variable overhead expenses, are assigned to inventories held by the method most appropriate to the class of inventory, with the majority being valued on a standard cost basis. Net realizable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale.

Provisions

Provisions are recognized when the Company has a present obligation as a result of a past event, it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the balance sheet date, considering the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received, and the amount of the receivable can be measured reliably.

Warranty provisions

The Company generally offers 2-6 years warranties for its prosthetics products. Warranty provisions include expected warranty costs for products sold with standard warranty and are recognized at the date of sale of the relevant products, at management´s best estimate of the expenditure required to settle the Company's obligation. Management estimates the related provision for future warranty claims based on historical warranty claim information, as well as recent information on parts and labor costs. The assumptions made in relation to the current period are consistent with those in prior year.

Restructuring provisions

Restructuring provision is recognized when the Company has developed a detailed formal plan for the restructuring and has started to implement it or announcing its main features to those affected by it. The measurement of a restructuring provision includes only the direct expenditures arising from the restructuring, which are those amounts that are both necessarily entailed by the restructuring and not associated with the ongoing activities of the entity.

Other provisions

Other provisions mainly consist of legal and employee related provisions.

Financial instruments

Financial instruments are financial assets and financial liabilities. They are recognized in the Company's balance sheet when the Company becomes a party to the contractual provisions of the instrument and are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial instruments (other than financial assets and financial liabilities at fair value through profit or loss) are instruments, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial instruments at fair value through profit or loss are recognized immediately in profit or loss.

Notes to the Consolidated Financial Statements

Effective interest method

The effective interest method is a method of calculating the amortized cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees on points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument or, where appropriate, a shorter period to the net carrying amount on initial recognition.

Income is recognized on an effective interest basis for debt instruments other than those financial assets classified as at fair value through profit or loss (FVTPL).

Financial assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. All recognized financial assets are measured subsequently in their entirety at either amortized cost or fair value, depending on the classification of the financial assets.

Classification of financial assets

Debt instruments that meet the following conditions are measured subsequently at amortized cost:

- the financial asset is held within a business model whose objective is to hold financial assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets that do not meet the criteria for being measured at amortized cost are measured at FVTPL. Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognized in profit or loss to the extent they are not part of a designated hedging relationship. The net gain or loss recognized in profit or loss includes any dividend or interest earned on the financial asset. Fair value is determined in the manner described in Basis of preparation above.

Impairment of financial assets

The Company recognizes a loss allowance for expected credit losses on investments in debt instruments that are measured at amortized cost and account receivables. The amount of expected credit loss (ECL) is updated at each reporting date to reflect changes in credit risk from initial recognition of the respective financial instrument. The company applies the IFRS 9 simplified approach to measuring ECL’s which uses a lifetime expected loss allowance for accounts receivables. The ECL on accounts receivable is estimated using a provision matrix by reference to past default experience, general economic conditions and an assessment of both the current as well as expected conditions, including time value of money where appropriate. Individual allowance and adjustments to the collective allowance are made based on the individual assessment of customers' situation and probability of incoming payments. As the Company´s historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished between the Company´s different geographical segments.

A financial asset is credit-impaired when one or more events, that have a detrimental impact on the estimated future cash flows of that financial asset, have occurred. Evidence that a financial asset is credit-impaired includes observable data about significant financial difficulty of the borrower. An allowance for credit-impaired financial assets is measured on an individual basis.

The Company writes off a financial asset when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the debtor has been placed under liquidation or has entered into bankruptcy

Notes to the Consolidated Financial Statements

proceedings. Financial assets written off may still be subject to enforcement activities under the Company's recovery procedures, taking into account legal advice where appropriate. Any recoveries made are recognized in profit or loss.

Derecognition of financial assets

The Company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity.

On derecognition of a financial asset, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognized in profit or loss.

Financial liabilities

All financial liabilities are measured subsequently at amortized cost using the effective interest method or at FVTPL.

Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combinations, (ii) held for trading or (iii) it is designated as at FVTPL.

A financial liability is classified as held for trading if:

- it has been acquired principally for the purpose of repurchasing it in the near term; or
- on initial recognition it is part of a portfolio of identified financial instruments that the Company manages together and has a recent actual pattern of short-term profit-taking; or
- it is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument.

Derecognition of financial liabilities

The Company derecognizes financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss. When the Company exchanges with the existing lender one debt instrument into another one with the substantially different terms, such exchange is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, the Company accounts for substantial modification of terms of an existing liability, or part of it, as an extinguishment of the original financial liability and the recognition of a new liability. It is assumed that the terms are substantially different if the discounted present value of the cash flows under the new terms, including any fees paid net of any fees received and discounted using the original effective rate, is at least 10 % different from the discounted present value of the remaining cash flows of the original financial liability. If the modification is not substantial, the difference between the carrying amount of the liability before the modification and the present value of the cash flows after modification, should be recognized in income statement as modification gain or loss.

Employee benefits

Retirement benefit costs

Payments to defined contribution retirement benefit plans are recognized as an expense when employees have rendered service entitling them to the contributions.

A liability is recognized in respect of wages and salaries, annual leave and sick leave in the period the related service is rendered at the undiscounted amount of the benefits expected to be paid in exchange for that service.

Notes to the Consolidated Financial Statements

Derivative financial instruments

The Company enters into derivative financial instruments to manage its exposure to currency risk. Further details of derivative financial instruments are disclosed in note 34.

Derivatives are initially recognized at fair value at the date a derivative contract is entered into, and are subsequently remeasured to their fair value at each balance sheet date. The resulting gain or loss is recognized in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship. The Company designates certain derivatives as either hedges of cash flow of recognized liabilities or hedges of net investments in foreign operations.

A derivative is presented as a non-current asset or a non-current liability if the remaining maturity of the instrument is more than 12 months and it is not expected to be realized or settled within 12 months. Other derivatives are presented as current assets or current liabilities.

Hedge accounting

The Company designates certain hedging instruments, which include derivatives and non-derivatives in respect of foreign currency risk, as either cash flow hedges or hedges of net investment in foreign operations.

At the inception of the hedge relationship the entity documents the relationship between the hedging instrument and hedged item, along with its risk management objectives and its strategy for undertaking various hedge transactions. Furthermore, at the inception of the hedge and on an ongoing basis, the Company documents whether the hedging instrument, that is used in a hedging relationship, is effective in offsetting changes in fair values or cash flows of the hedged item attributable to the hedge risk, which is when the hedging relationships meet all of the following hedge effectiveness requirements:

- there is an economic relationship between the hedged item and the hedging instrument;
- the effect of credit risk does not dominate the value changes that result from that economic relationship; and
- the hedge ratio of the hedging relationship is the same as that resulting from the quantity of the hedged item that the Company actually hedges and the quantity of the hedging instrument that the Company actually uses to hedge that quantity of hedged item.

If a hedging relationship ceases to meet the hedge effectiveness requirement relating to the hedge ratio, but the risk management objective for that designated hedging relationship remains the same, the Company adjusts the hedge ratio of the hedging relationship (i.e., rebalances the hedge) so that it meets the qualifying criteria again.

The hedging reserve within equity represents the cumulative portion of gains and losses on hedging instruments deemed effective in cash flow hedges. The cumulative deferred gain or loss on the hedging instrument is reclassified to profit or loss only when the hedged transaction affects the profit or loss, or is included as a basis adjustment to the non-financial hedged item, consistent with the relevant accounting policy.

Hedges of net investments in foreign operations

Any gain or loss on the hedging instrument relating to the effective portion of the hedge is recognized in equity in the foreign currency translation reserve.

Gains and losses deferred in the foreign currency translation reserve are recognized in profit or loss on disposal of the foreign operation.

Notes to the Consolidated Financial Statements

41. Definitions of key ratios and terms

EBT
Earnings before interest

EBIT
Earnings before interest and taxes

EBITDA
Earnings before interest, taxes, depreciation and amortization. Financial items and share in net profit or loss of associated companies are not included in the EBITDA measurement

EBITDA before special items
Management monitors the performance measure EBITDA before special items, at a consolidated level and considers the measure relevant to an understanding of the Company's financial performance as it facilitates a better comparison of the Consolidated Income Statement between periods. Special items comprise material amounts of a non-recurring nature, such as costs relating to divestments, closure or restructuring, lawsuits, etc.

Aggregate EBITDA of Guarantors
Aggregate EBITDA of Guarantors is the combined EBITDA of the Company´s Guarantors as defined in loan agreements.

Aggregate gross assets of Guarantors
Aggregate gross assets of the Guarantors is the combined gross assets of the Company´s Guarantors as defined in loan agreements.

Gross profit margin
Gross profit as a percentage of net sales

EBITDA margin
EBITDA as a percentage of revenues

EBIT margin
EBIT as a percentage of revenues

Free cash flow
Cash generated from operating activities less capital expenditure

Equity ratio
Equity as a percentage of total assets

Net interest-bearing debt (NIBD) to EBITDA before special items
Aggregated interest bearing debt, consisting of borrowings and lease liabilities, less cash and cash equivalents divided by EBITDA before special items

Return on equity
Net profit as a percentage of average equity

Capex to net sales
The amount of purchased fixed and intangible assets to net sales

Market value of equity
Value of the Company's equity, measured by multiplying the current stock price by the total number of outstanding shares

Notes to the Consolidated Financial Statements

Sales growth
The change in revenue compared to prior period

Basic Earnings per share
Net profit attributable to the parent Company's shareholders, divided by the parent Company's average number of shares outstanding for the period

Diluted Earnings per share
Net profit attributable to the parent Company's shareholders, divided by the parent Company's average number of shares outstanding for the period adjusted for effects of outstanding share option contracts.

© Embla Medical, 2026